Tearsheet

Amneal Pharmaceuticals (AMRX)

Market Price (6/20/2026): $16.21 | Market Cap: $5.1 BilSector: Health Care | Industry: Pharmaceuticals

Amneal Pharmaceuticals (AMRX)

Market Price (6/20/2026): $16.21
Market Cap: $5.1 Bil
Sector: Health Care
Industry: Pharmaceuticals

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

Attractive cash flow generation
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 10%

Low stock price volatility
Vol 12M is 32%

Megatrend and thematic drivers
Megatrends include Aging Population & Chronic Disease, and Precision Medicine. Themes include Geriatric Care, Oncology Treatments, Show more.

Trading close to highs
Dist 52W High is -0.8%, Dist 3Y High is -0.8%

Expensive valuation multiples
P/EPrice/Earnings or Price/(Net Income) is 42x

Stock price has recently run up significantly
12M Rtn12 month market price return is 104%

Key risks
AMRX key risks include [1] substantial legal exposure from specific opioid and antitrust litigation, Show more.

0	Attractive cash flow generation CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 10%
1	Low stock price volatility Vol 12M is 32%
2	Megatrend and thematic drivers Megatrends include Aging Population & Chronic Disease, and Precision Medicine. Themes include Geriatric Care, Oncology Treatments, Show more.
3	Trading close to highs Dist 52W High is -0.8%, Dist 3Y High is -0.8%
4	Expensive valuation multiples P/EPrice/Earnings or Price/(Net Income) is 42x
5	Stock price has recently run up significantly 12M Rtn12 month market price return is 104%
6	Key risks AMRX key risks include [1] substantial legal exposure from specific opioid and antitrust litigation, Show more.

AMRX in ETFs

Weight = AMRX's share of each fund

VTI0.00%

ITOT0.00%

IWM0.07%

IJR0.13%

VB0.03%

SLYG0.19%

IJT0.15%

SLYV0.13%

+14 more covered ETFs

Valuation & Metrics

FYE: 12/31	Forward FYE		Now	Historical (CYE & TTM)
	2027	2026	6/20/26	2025	2024	2023	2022
Share Price			$16.21	$12.60	$7.92	$6.07	$1.99
Mkt Cap ($ Bil)			5.1	4.0	2.5	1.5	0.3
+ Debt ($ Bil)			2.7	2.7	2.6	2.8	2.8
- Cash ($ Bil)			0.2	0.3	0.1	0.1	0.0
TEV ($ Bil)			7.6	6.7	5.1	4.3	3.1
Valuation Ratios
P/S	1.5	1.7	1.7	1.3	0.9	0.6	0.1
P/EBIT	15.9	17.1	12.2	10.4	12.1	8.7	-3.4
P/E	14.0	16.1	41.9	55.0	-21.0	-17.7	-2.3
P/FCF	—	—	27.2	17.6	11.1	5.4	-11.8
Sector Ratios (* = sector average)
P/S *			3.7	4.2	3.8	4.2	4.6
P/EBIT *			-1.8	-1.7	-1.5	-1.6	-1.3
P/E *			-1.8	-1.8	-1.7	-1.7	-1.3
P/FCF *			-1.8	-1.8	-1.5	-1.6	-1.6

FYE: 12/31	Forward FYE		Now
	2027	2026	6/20/26
Share Price			$16.21
Mkt Cap ($ Bil)			5.1
+ Debt ($ Bil)			2.7
- Cash ($ Bil)			0.2
TEV ($ Bil)			7.6
Valuation Ratios
P/S	1.5	1.7	1.7
P/EBIT	15.9	17.1	12.2
P/E	14.0	16.1	41.9
P/FCF	—	—	27.2
Sector Ratios (* = sector average)
P/S *			3.7
P/EBIT *			-1.8
P/E *			-1.8
P/FCF *			-1.8

FYE: 12/31	AMRX [1]	S&P 500 [2]
REVENUE GROWTH
LTM Revenue [3]	$3.0 Bil	—
FY 2026 Sales	$3.1 Bil	—
FY 2027 Sales	$3.3 Bil	—
FY 2026 Sales Growth	1.7%	—
FY 2027 Sales Growth	7.7%	7.7%
EARNINGS
LTM Net Income (GAAP) [3]	$122.1 Mil	—
FY 2026 Net Income (Non-GAAP)	$318.9 Mil	—
FY 2027 Net Income (Non-GAAP)	$365.8 Mil	—
FY 2027 Net Income Growth	14.7%	15.0%
FY 2026 EPS (Non-GAAP)	$0.98	—
FY 2027 EPS (Non-GAAP)	$1.13	—
FY 2027 EPS Growth	14.7%	—
VALUATION
FY 2026 P/S	1.7	3.2
FY 2027 P/S	1.5	—
FY 2026 P/E	16.1	20.5
FY 2027 P/E	14.0	—

[1] AMRX forward figures are analyst consensus for the next two fiscal years (fiscal year end 12/31). Net Income and EPS are non-GAAP (adjusted) consensus. P/S and P/E divide the current market cap by the consensus figure.
[2] S&P 500 figures are the SPY ETF's holdings-weighted forward aggregate. P/S and P/E reflect FY1/FY2 consensus blended to the 12-month window ending 6/30/27 (~one year forward), shown when ≥90% of index weight has estimates. Growth is the aggregate next-fiscal-year vs current-fiscal-year (FY1→FY2) change. Index-level dollar Sales, Net Income and EPS are not applicable.
[3] LTM = reported trailing-twelve-month actuals (GAAP).

	AMRX	S&P 500
REVENUE GROWTH	FAIR
Rev LTM ($ Bil)	3.0
Rev Chg Q	3.9%	8.8%
Rev Chg LTM	7.6%	7.4%
Rev Chg 3Y Avg	10.3%	5.8%
PROFITABILITY	POOR
Op Inc LTM ($ Bil)	0.4
CFO LTM ($ Bil)	0.3
Net Inc LTM ($ Bil)	0.1
Op Mgn LTM	14.6%	18.4%
CFO/Rev LTM	10.0%	21.3%
Net Inc Mgn	4.0%	13.0%
VALUATION	HIGH
P/S	1.7	3.2
P/CFO	16.7	14.9
P/FCF	27.2	19.1
P/E	41.9	24.0
STABILITY	FAIR
Debt/Equity	0.53	0.21
Cash/Assets	0.06	0.07

AI Analysis | Feedback

Metric	Value	Date	Source
Number of Parkinson's patients on CREXONT® therapy	approximately 17,000	10302025	Link
Total commercial injectable products	over 40	6052024	Link
Commercial biosimilar portfolio	3	10302025	Link
Pending Abbreviated New Drug Applications (ANDAs)	69	10302025	Link
Products in development	44	10302025	Link
Peak U.S. sales potential for Brekiya®	$50 million - $100 million	10302025	Link
Peak U.S. sales potential for CREXONT®	$300 million - $500 million	10302025	Link
Total pharmaceutical product portfolio	over 290	10302025	Link
New products launched in 2025 (year-to-date)	17	10302025	Link
Percentage of complex products in development pipeline	95%	10302025	Link

Price Chart

No Events

Why The Stock Moved

Qualitative Assessment

AI Analysis | Feedback

Updated on 6/11/2026

Amneal Pharmaceuticals (AMRX) stock has gained about 15% since 2/28/2026 because of the following key factors:

1. Strong fiscal Q1 2026 financial performance and raised full-year guidance fueled investor confidence. Amneal Pharmaceuticals reported adjusted diluted EPS of $0.27 for fiscal Q1 2026, which ended March 31, 2026, significantly surpassing analysts' consensus estimate of $0.17 by 58.82%. Net revenue for the quarter increased by 4% year-over-year to $723 million, driven by growth in both its Specialty and Affordable Medicines segments. Following these strong results, the company affirmed its previously announced increase in full-year 2026 guidance, projecting adjusted EBITDA of $720 million to $760 million and adjusted EPS of $0.93 to $1.03.

2. Strategic acquisition of Kashiv BioSciences enhanced Amneal's biosimilar leadership and long-term growth prospects. On April 22, 2026, Amneal announced an agreement to acquire Kashiv BioSciences. This acquisition, which includes an upfront payment of approximately $750 million in a 50/50 cash and equity split, is expected to create a fully integrated global biosimilar leader. This strategic move is anticipated to accelerate Amneal's growth through an expanded biosimilar pipeline and diversified business mix, aiming to close the valuation gap with industry peers.

3. Positive drug development news, including new FDA approvals and promising clinical trial results, reinforced the company's product pipeline and market position. In early June 2026, Amneal received U.S. FDA approval for its romidepsin injection solution for cutaneous T-cell lymphoma, securing 180 days of Competitive Generic Therapy exclusivity. This approval highlights the company's expansion into higher-value injectables. Additionally, positive interim Phase 4 ELEVATE-PD results for CREXONT in Parkinson's disease were reported in early June 2026, showing meaningful gains in "Good On" time and motor control, further supporting the company's branded expansion strategy.

4. Sustained positive analyst sentiment and "Strong Buy" ratings contributed to upward stock momentum. As of June 10, 2026, Amneal Pharmaceuticals maintained a consensus "Strong Buy" rating from analysts. The average price target of $17.25 represents a potential upside of 17.43% from the stock's price on June 9, 2026. This unanimous bullish sentiment from analysts, with some initiating coverage with a "Strong Buy" rating and a price target of $19.00, reflects increased confidence in Amneal's biosimilar strategy and growth trajectory.

Show less

Holding a concentrated position? Know your true downside before the momentum shifts.

Protect Your Wealth →

Stock Movement Drivers

Fundamental Drivers

The 17.4% change in AMRX stock from 2/28/2026 to 6/19/2026 was primarily driven by a 68.0% change in the company's Net Income Margin (%).

(LTM values as of)	2282026	6192026	Change
Stock Price ($)	13.81	16.21	17.4%
Change Contribution By:
Total Revenues ($ Mil)	3,019	3,046	0.9%
Net Income Margin (%)	2.4%	4.0%	68.0%
P/E Multiple	60.3	41.9	-30.4%
Shares Outstanding (Mil)	314	316	-0.5%
Cumulative Contribution			17.4%

LTM = Last Twelve Months as of date shown

Market Drivers

2/28/2026 to 6/19/2026

	Return	Correlation
AMRX	17.4%
Market (SPY)	9.2%	35.8%
Sector (XLV)	-6.4%	49.8%

Fundamental Drivers

The 29.5% change in AMRX stock from 11/30/2025 to 6/19/2026 was primarily driven by a 1894.4% change in the company's Net Income Margin (%).

(LTM values as of)	11302025	6192026	Change
Stock Price ($)	12.52	16.21	29.5%
Change Contribution By:
Total Revenues ($ Mil)	2,935	3,046	3.8%
Net Income Margin (%)	0.2%	4.0%	1894.4%
P/E Multiple	666.7	41.9	-93.7%
Shares Outstanding (Mil)	314	316	-0.6%
Cumulative Contribution			29.5%

LTM = Last Twelve Months as of date shown

Market Drivers

11/30/2025 to 6/19/2026

	Return	Correlation
AMRX	29.5%
Market (SPY)	9.9%	29.5%
Sector (XLV)	-4.4%	39.1%

Fundamental Drivers

The 121.4% change in AMRX stock from 5/31/2025 to 6/19/2026 was primarily driven by a 109.1% change in the company's P/S Multiple.

(LTM values as of)	5312025	6192026	Change
Stock Price ($)	7.32	16.21	121.4%
Change Contribution By:
Total Revenues ($ Mil)	2,830	3,046	7.6%
P/S Multiple	0.8	1.7	109.1%
Shares Outstanding (Mil)	311	316	-1.6%
Cumulative Contribution			121.4%

LTM = Last Twelve Months as of date shown

Market Drivers

5/31/2025 to 6/19/2026

	Return	Correlation
AMRX	121.4%
Market (SPY)	28.1%	34.9%
Sector (XLV)	14.6%	43.5%

Fundamental Drivers

The 592.7% change in AMRX stock from 5/31/2023 to 6/19/2026 was primarily driven by a 973.7% change in the company's P/S Multiple.

(LTM values as of)	5312023	6192026	Change
Stock Price ($)	2.34	16.21	592.7%
Change Contribution By:
Total Revenues ($ Mil)	2,272	3,046	34.0%
P/S Multiple	0.2	1.7	973.7%
Shares Outstanding (Mil)	152	316	-51.9%
Cumulative Contribution			592.7%

LTM = Last Twelve Months as of date shown

Market Drivers

5/31/2023 to 6/19/2026

	Return	Correlation
AMRX	592.7%
Market (SPY)	85.7%	33.7%
Sector (XLV)	22.9%	32.3%

Return vs. Risk

Price Returns Compared

	2021	2022	2023	2024	2025	2026	Total [1]
Returns
AMRX Return	5%	-58%	205%	30%	59%	29%	256%
Peers Return	26%	30%	18%	7%	33%	-3%	167%
S&P 500 Return	27%	-19%	24%	23%	16%	8%	98%
Monthly Win Rates [3]
AMRX Win Rate	58%	33%	75%	50%	67%	83%
Peers Win Rate	53%	67%	50%	44%	64%	43%
S&P 500 Win Rate	75%	42%	67%	75%	67%	50%
Max Drawdowns [4]
AMRX Max Drawdown	-46%	-60%	-53%	-17%	-23%	-22%
Peers Max Drawdown	-17%	-13%	-15%	-22%	-24%	-15%
S&P 500 Max Drawdown	-5%	-25%	-10%	-8%	-19%	-9%

[1] Cumulative total returns since the beginning of 2021
[2] Peers: OPTH, TRLV, LLY, JNJ, MRK.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 6/18/2026 (YTD)

Event	AMRX	S&P 500
2025 US Tariff Shock
% Loss	-11.2%	-18.8%
% Gain to Breakeven	12.6%	23.1%
Time to Breakeven	22 days	79 days
2023 SVB Regional Banking Crisis
% Loss	-47.3%	-6.7%
% Gain to Breakeven	89.8%	7.1%
Time to Breakeven	65 days	31 days
2022 Inflation Shock & Fed Tightening
% Loss	-59.6%	-24.5%
% Gain to Breakeven	147.4%	32.4%
Time to Breakeven	420 days	427 days
2020 COVID-19 Crash
% Loss	-49.7%	-33.7%
% Gain to Breakeven	98.8%	50.9%
Time to Breakeven	71 days	140 days

Compare to OPTH, TRLV, LLY, JNJ, MRK

In The Past

Amneal Pharmaceuticals's stock fell -11.2% during the 2025 US Tariff Shock. Such a loss loss requires a 12.6% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

Event	AMRX	S&P 500
2023 SVB Regional Banking Crisis
% Loss	-47.3%	-6.7%
% Gain to Breakeven	89.8%	7.1%
Time to Breakeven	65 days	31 days
2022 Inflation Shock & Fed Tightening
% Loss	-59.6%	-24.5%
% Gain to Breakeven	147.4%	32.4%
Time to Breakeven	420 days	427 days
2020 COVID-19 Crash
% Loss	-49.7%	-33.7%
% Gain to Breakeven	98.8%	50.9%
Time to Breakeven	71 days	140 days

Compare to OPTH, TRLV, LLY, JNJ, MRK

In The Past

Amneal Pharmaceuticals's stock fell -11.2% during the 2025 US Tariff Shock. Such a loss loss requires a 12.6% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Amneal Pharmaceuticals (AMRX)

Business Description Analogies Products Customers Suppliers Management Key Risks Emerging Threats Market Size Revenue Drivers Capital Allocation

Amneal Pharmaceuticals (AMRX) is a global pharmaceutical company focused on the development, manufacturing, and distribution of a broad portfolio of both generic and specialty (branded) pharmaceutical products. The company's operations encompass various therapeutic areas and dosage forms, reflecting its commitment to serving a wide range of medical needs across the United States and international markets.

Its business is segmented into three main areas. The Generics segment produces an extensive array of complex oral solids, injectables, ophthalmics, and other formulations across numerous therapeutic categories. The Specialty segment develops and promotes branded prescription drugs, including Emverm for parasitic infections, Rytary for Parkinson's disease, and Unithroid for hypothyroidism, with a focus on central nervous system disorders and endocrinology. Additionally, the AvKARE segment provides pharmaceuticals, medical supplies, and related services, primarily to governmental agencies.

Amneal Pharmaceuticals serves a diverse customer base, including wholesalers, distributors, hospitals, and a variety of chain and individual pharmacies. A significant part of its customer base, particularly through the AvKARE segment, includes governmental entities such as the Department of Defense and the Department of Veterans Affairs. The company also engages in wholesale distribution and packaging of pharmaceuticals and vitamins for retail and institutional customers.

AI Analysis | Feedback

Here are a few brief analogies for Amneal Pharmaceuticals (AMRX):

Like a Procter & Gamble or Unilever for the pharmaceutical industry, managing a broad portfolio of both essential generic medications and specialized branded treatments.
Imagine the pharmaceutical equivalent of Aldi or Lidl, primarily offering a wide range of affordable generic medications, but also developing and distributing specific branded drugs for specialty areas.

AI Analysis | Feedback

Major Products and Services of Amneal Pharmaceuticals (AMRX)

Generic Pharmaceutical Products: A broad portfolio of generic medications offered in various dosage forms and therapeutic areas.
Emverm: A branded chewable tablet for the treatment of various parasitic worm infections.
Rytary: A branded medication specifically used to treat Parkinson's disease.
Unithroid: A branded medication prescribed for the treatment of hypothyroidism.
Pharmaceutical and Medical/Surgical Product Distribution: Wholesale distribution, packaging, and supply of pharmaceuticals, medical, and surgical products, particularly to governmental agencies.

AI Analysis | Feedback

Amneal Pharmaceuticals (AMRX) sells its products primarily to other companies and governmental agencies, rather than directly to individuals. Its major customers can be categorized as follows:

Pharmaceutical Wholesalers and Distributors: These companies purchase Amneal's products in bulk for redistribution. Examples of major players in this segment include:
- McKesson Corporation (MCK)
- Cardinal Health, Inc. (CAH)
- AmerisourceBergen Corporation (ABC)
Pharmacies: This includes both large chain pharmacies and individual pharmacies that dispense medications to consumers. Prominent chain pharmacies include:
- CVS Health Corporation (CVS)
- Walgreens Boots Alliance, Inc. (WBA)
Hospitals and Institutional Customers: Healthcare facilities that administer pharmaceuticals to patients.
Governmental Agencies: Through its AvKARE segment, Amneal Pharmaceuticals provides products and services primarily to:
- The Department of Defense
- The Department of Veterans Affairs

AI Analysis | Feedback

null

AI Analysis | Feedback

Chirag Patel, Co-Chief Executive Officer and President

Chirag Patel is a Co-Founder of Amneal Pharmaceuticals, established in 2002. He served as Co-Chairman and Co-Chief Executive Officer of Amneal from 2005 until the company's combination with Impax Laboratories in 2018, and subsequently returned as Co-Chief Executive Officer and President in August 2019. Mr. Patel has also invested in several independent biopharmaceutical companies, including Asana Biosciences, Kashiv Biosciences, and Prolong Pharmaceuticals. Earlier in his career, he co-founded NextGen Technologies and Veriprise Wireless.

Chintu Patel, Co-Chief Executive Officer

Chintu Patel is a Co-Founder of Amneal Pharmaceuticals, which he established in 2002 with his brother Chirag Patel. He served as Co-Chairman and Co-Chief Executive Officer of Amneal from 2005 until the combination with Impax Laboratories in 2018, and returned as Co-Chief Executive Officer in August 2019.

Tasos Konidaris, Executive Vice President, Chief Financial Officer

Tasos Konidaris was appointed Senior Vice President, Chief Financial Officer, effective March 12, 2020. Before joining Amneal, he spent seven years as Senior Vice President and Chief Financial Officer of Dun & Bradstreet Corporation. Mr. Konidaris previously held various financial and general management positions at Schering-Plough Corporation, Pharmacia Corporation, Novartis Corporation, and Bristol-Myers Squibb. From 2011 to 2015, he served as Executive Vice President, Chief Financial Officer, and Head of Corporate Development of Ikaria, Inc., where he was responsible for finance and corporate development functions, including driving growth through licensing and acquisitions.

Nikita Shah, Executive Vice President, Chief Human Resources Officer

Nikita Shah serves as the Executive Vice President, Chief Human Resources Officer for Amneal Pharmaceuticals.

Jason B. Daly, Esq., Executive Vice President, Chief Legal Officer & Corporate Secretary

Jason B. Daly, Esq. holds the position of Executive Vice President, Chief Legal Officer & Corporate Secretary at Amneal Pharmaceuticals.

AI Analysis | Feedback

The key risks to Amneal Pharmaceuticals (AMRX) primarily stem from the highly competitive and regulated nature of the pharmaceutical industry, particularly within its significant Generics segment.

Pricing Pressure and Intense Competition in the Generics Market: Amneal faces significant pricing pressures and intense competition within the generic drug market, which can lead to compressed margins and impact profitability. This competitive landscape includes larger companies with extensive resources, established distribution networks, and robust pricing strategies.
Regulatory Risks and Delays in Approvals: The company is subject to increasing regulatory scrutiny and the risk of delays in FDA approvals for its generic and specialty products, which can directly affect product launch timelines and revenue growth. Changes in FDA product approval requirements, review processes, and legislative efforts by branded companies to limit generic substitution or file patent infringement suits further contribute to these regulatory challenges.
Litigation, including Patent Challenges and Opioid-Related Liabilities: Amneal operates in an industry prone to legal challenges, encompassing patent infringement suits by branded pharmaceutical companies that can delay generic market entry, as well as significant industry-wide settlements such as ongoing opioid litigation liabilities.

AI Analysis | Feedback

The emergence and growth of direct-to-consumer pharmacy models, such as Mark Cuban Cost Plus Drugs, poses a clear emerging threat. These models aim to bypass traditional pharmaceutical distribution channels, including wholesalers, pharmacy benefit managers, and retail pharmacies, by offering generic drugs at significantly lower and more transparent prices directly to consumers. This directly threatens the established distribution and pricing models that Amneal Pharmaceuticals' Generics segment heavily relies upon, potentially leading to increased price erosion for its products and a shift in market share away from its traditional sales channels (wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies).

AI Analysis | Feedback

Amneal Pharmaceuticals (AMRX) operates in several addressable markets through its Generics, Specialty, and AvKARE segments. The market sizes for its main products and services are outlined below:

Generics Segment

The global generic pharmaceuticals market was valued at approximately USD 362.9 billion in 2022 and is projected to reach around USD 812.98 billion by 2032, growing at a CAGR of 8.4% during the forecast period from 2023 to 2032. Other estimates place the global market size at USD 437.9 billion in 2024, projected to reach USD 1005.74 billion by 2035 with a CAGR of 7.85% from 2025 to 2035. Another report states a global market size of USD 454.7 billion in 2025, expected to reach USD 770.0 billion by 2033.
In North America, the generic pharmaceuticals market was the largest region in 2025. The U.S. generic drugs market was valued at USD 136,451.6 million in 2025 and is expected to reach USD 220,129.9 million by 2033, growing at a CAGR of 5.8% from 2026 to 2033. Another source estimates the U.S. generic drugs market size at USD 146.04 billion in 2025, projected to increase to approximately USD 243.70 billion by 2035.

Specialty Segment

Central Nervous System (CNS) Disorders

The global central nervous system (CNS) therapeutics market was valued at USD 163.8 billion in 2025 and is expected to grow to USD 412.1 billion by 2034, registering a CAGR of 10.8% from 2025 to 2034. Other estimates for the global CNS therapeutics market include USD 138.59 billion in 2025, projected to reach USD 273.32 billion by 2033, and USD 126.68 billion in 2025, projected to reach USD 236.94 billion by 2034.
The U.S. CNS therapeutics market is anticipated to reach a value of USD 56.1 billion in 2025 and continue expanding to USD 133.7 billion by 2034, at a CAGR of 10.1%.

Endocrinology

The global endocrinology drugs market grew from USD 65.43 billion in 2025 to USD 70.12 billion in 2026 and is projected to register a CAGR of 7.67%, reaching USD 109.78 billion by 2032. Another report estimates the market size at USD 107.79 billion in 2025, and it is expected to reach USD 144.86 billion by 2030.
North America holds a majority share in the endocrinology drugs market, valued at USD 40.0 billion in 2024, expected to grow to USD 56.0 billion by 2035.

Parasitic Infections (Emverm)

The global antiparasitic drugs market size was estimated at USD 19.44 billion in 2024 and is predicted to increase from USD 20.44 billion in 2025 to approximately USD 31.85 billion by 2034. Another source valued the global antiparasitic drugs market at USD 22.7 billion in 2023, projected to reach USD 37.38 billion by 2032.
Specifically for mebendazole, the global market size was valued at approximately USD 250 million in 2023 and is projected to reach around USD 400 million by 2032. The global mebendazole market size was estimated at USD 145.91 million in 2025 and is projected to reach USD 357.87 million by 2035.

Parkinson's Disease (Rytary)

The global Parkinson's disease drugs market size was valued at USD 7.75 billion in 2025 and is projected to grow to USD 15.77 billion by the end of 2034. Another estimate places the global Parkinson's disease treatment market size at USD 5.65 billion in 2024, expected to reach USD 7.58 billion by 2030.
The global Parkinson's disease drug market was valued at approximately USD 4 billion in 2022, with an anticipated CAGR of 6% until 2030. In 2021, the global Parkinson's disease drugs market size was valued at USD 5.7 billion and is projected to reach USD 10.4 billion by 2031.
The Parkinson's Disease Market Size in the US was approximately USD 1,883 million in 2023.
Rytary captured about 15-20% of the Parkinson's medication market share in the US by mid-2022.

Hypothyroidism (Unithroid)

The global hypothyroidism drug market is projected to reach USD 14.55 billion by 2025. Other projections estimate the global hypothyroidism market size at USD 2,397.71 million in 2025, expected to increase to USD 3,274.78 million by 2032.
The global thyroid gland disorder treatment market size was valued at USD 2.22 billion in 2023 and is projected to grow at a CAGR of 3.6% from 2024 to 2030. Hypothyroidism dominated this market, accounting for a 68.7% share in 2023.
The U.S. thyroid hormone replacement market was valued at approximately USD 1.9 billion in 2022. In this market, Unithroid held an estimated 15-20% market share among generic and branded levothyroxine products in 2022.

AI Analysis | Feedback

Amneal Pharmaceuticals (AMRX) is expected to drive future revenue growth over the next 2-3 years through several key initiatives across its segments:

Acceleration in Complex Generics and Injectables: The company anticipates a meaningful acceleration in revenue growth within its Affordable Medicines segment in 2026 and 2027, propelled by an expanding portfolio of complex, differentiated, and durable products. Amneal plans to file 10-15 key complex programs in 2026 and aims for 20-30 new Affordable Medicines launches annually.
Expansion of Biosimilars Portfolio: Biosimilars remain a central pillar of Amneal's growth strategy, with the company on track to have six U.S. biosimilars by 2027. This includes two recently approved products and Omalizumab (targeting the Xolair market) under review, reflecting a bold investment in growing these therapeutic offerings.
Growth in Specialty Segment Driven by New Branded Products: While the Specialty segment may experience flat revenue in 2026 due to generic erosion of Rytary, growth is expected to resume strongly in 2027 as new branded products gain traction. Notably, CREXONT is showing encouraging uptake, with management expecting to roughly double its market share and revenue in 2026, and a new migraine auto-injector is experiencing stronger-than-expected early demand.
Entry into the GLP-1 Market: Amneal's collaboration with Pfizer in the GLP-1 space is progressing, with two dedicated manufacturing facilities on schedule. This positions the company to establish a foothold in this rapidly growing therapeutic class, offering a significant new revenue stream.

AI Analysis | Feedback

Share Issuance

As of February 14, 2025, Amneal Pharmaceuticals had 309,966,341 shares of Class A common stock outstanding.
The company's guidance for the year ending December 31, 2025, assumed approximately 325 million to 330 million weighted-average diluted shares outstanding.
Total shares outstanding were 314.08 million as of November 5, 2025.

Capital Expenditures

Amneal Pharmaceuticals estimated approximately $120.0 million would be invested during 2025 for capital expenditures.
The primary focus for 2025 capital expenditures included manufacturing equipment, information technology, and facilities to support and grow existing operations, as well as investments for a collaboration and supply agreement with Metsera, Inc.
Annual capital expenditures were approximately $70.06 million in 2025, $74.99 million in 2024, and $69.19 million in 2023.

Interactive Breakdown

null

null

Better Bets vs. Amneal Pharmaceuticals (AMRX)

INDUSTRY: Pharmaceuticals

Higher Rev Chg 3Y Avg | Lower P/S (Values for AMRX: 10.3% | 1.7x)

PAHC (15.8% | 0.9x)

Phibro Animal Health

COLL (15.0% | 1.4x)

Collegium Pharmaceutical

AMPH (12.3% | 1.2x)

Amphastar Pharmaceuticals

TLRY (13.2% | 0.6x)

Tilray Brands

EOLS (25.1% | 1.4x)

Evolus

Higher Rev Chg 3Y Avg | Lower P/Op Inc (Values for AMRX: 10.3% | 11.5x)

PAHC (15.8% | 7.2x)

Phibro Animal Health

COLL (15.0% | 5.7x)

Collegium Pharmaceutical

AMPH (12.3% | 7.3x)

Amphastar Pharmaceuticals

ESPR (86.0% | 10.4x)

Esperion Therapeutics

Higher Rev Chg LTM (Value for AMRX: 7.6%)

LLY (47.4%)

Eli Lilly

CORT (12.2%)

Corcept Therapeutics

ELAN (10.5%)

Elanco Animal Health

JAZZ (9.2%)

Jazz Pharmaceuticals

JNJ (7.9%)

Johnson & Johnson

Higher Rev Chg 3Y Avg (Value for AMRX: 10.3%)

LQDA (639.8%)

Liquidia

LLY (37.9%)

Eli Lilly

CORT (23.2%)

Corcept Therapeutics

PTCT (19.4%)

PTC Therapeutics

ALKS (15.0%)

Alkermes

Higher Op Mgn LTM (Value for AMRX: 14.6%)

LLY (47.3%)

Eli Lilly

BMY (28.0%)

Bristol-Myers Squibb

JNJ (26.8%)

Johnson & Johnson

PFE (24.5%)

Pfizer

MRK (19.7%)

Merck

Higher CFO/Rev LTM (Value for AMRX: 10.0%)

LLY (28.3%)

Eli Lilly

BMY (27.4%)

Bristol-Myers Squibb

MRK (27.2%)

Merck

JNJ (23.7%)

Johnson & Johnson

PFE (18.9%)

Pfizer

Higher FCF/Rev LTM (Value for AMRX: 6.2%)

BMY (24.6%)

Bristol-Myers Squibb

MRK (21.5%)

Merck

JNJ (18.1%)

Johnson & Johnson

PFE (15.0%)

Pfizer

LLY (14.4%)

Eli Lilly

Higher Total Yield (Value for AMRX: 2.4%)

PFE (12.0%)

Pfizer

BMY (11.2%)

Bristol-Myers Squibb

JNJ (6.1%)

Johnson & Johnson

MRK (6.1%)

Merck

LLY (3.1%)

Eli Lilly

SECTOR: Health Care

Higher Rev Chg 3Y Avg | Lower P/S (Values for AMRX: 10.3% | 1.7x)

MCK (13.4% | 0.2x)

McKesson

CI (15.2% | 0.3x)

Cigna

HUM (12.8% | 0.3x)

Humana

CNC (10.7% | 0.2x)

Centene

BTSG (21.4% | 1.0x)

BrightSpring Health Services

Higher Rev Chg 3Y Avg | Lower P/Op Inc (Values for AMRX: 10.3% | 11.5x)

EHC (10.9% | 8.9x)

Encompass Health

HALO (29.1% | 9.6x)

Halozyme Therapeutics

OPCH (12.0% | 10.4x)

Option Care Health

ADMA (43.0% | 9.5x)

ADMA Biologics

HRMY (24.1% | 10.2x)

Harmony Biosciences

Higher Rev Chg LTM (Value for AMRX: 7.6%)

LLY (47.4%)

Eli Lilly

UNH (9.7%)

UnitedHealth

ABBV (9.5%)

AbbVie

AMGN (9.1%)

Amgen

JNJ (7.9%)

Johnson & Johnson

Higher Rev Chg 3Y Avg (Value for AMRX: 10.3%)

LLY (37.9%)

Eli Lilly

ISRG (18.1%)

Intuitive Surgical

CI (15.2%)

Cigna

MCK (13.4%)

McKesson

AMGN (12.5%)

Amgen

Higher Op Mgn LTM (Value for AMRX: 14.6%)

LLY (47.3%)

Eli Lilly

ABBV (33.2%)

AbbVie

AMGN (28.4%)

Amgen

JNJ (26.8%)

Johnson & Johnson

MRK (19.7%)

Merck

Higher CFO/Rev LTM (Value for AMRX: 10.0%)

ABBV (33.8%)

AbbVie

AMGN (28.9%)

Amgen

LLY (28.3%)

Eli Lilly

MRK (27.2%)

Merck

JNJ (23.7%)

Johnson & Johnson

Higher FCF/Rev LTM (Value for AMRX: 6.2%)

ABBV (31.8%)

AbbVie

AMGN (23.1%)

Amgen

MRK (21.5%)

Merck

JNJ (18.1%)

Johnson & Johnson

LLY (14.4%)

Eli Lilly

Higher Total Yield (Value for AMRX: 2.4%)

JNJ (6.1%)

Johnson & Johnson

MRK (6.1%)

Merck

UNH (5.5%)

UnitedHealth

ABBV (4.0%)

AbbVie

LLY (3.1%)

Eli Lilly

All Other Sectors

Higher Rev Chg 3Y Avg | Lower P/S (Values for AMRX: 10.3% | 1.7x)

PGR (19.9% | 1.3x)

Progressive

MFC (21.4% | 1.3x)

Manulife Financial

OKE (21.3% | 1.5x)

ONEOK

SLF (24.1% | 1.2x)

Sun Life Financial

CCL (23.1% | 1.6x)

Carnival Corporation

Higher Rev Chg 3Y Avg | Lower P/Op Inc (Values for AMRX: 10.3% | 11.5x)

ENB (13.7% | 10.7x)

Enbridge

NEM (30.0% | 8.3x)

Newmont

AEM (32.5% | 10.8x)

Agnico Eagle Mines

APO (41.0% | 10.9x)

Apollo Global Management

ADBE (11.0% | 8.6x)

Adobe

Higher Rev Chg LTM (Value for AMRX: 7.6%)

NVDA (70.7%)

NVIDIA

MSFT (17.9%)

Microsoft

GOOGL (17.5%)

Alphabet

AMZN (14.2%)

Amazon.com

AAPL (12.8%)

Apple

Higher Rev Chg 3Y Avg (Value for AMRX: 10.3%)

NVDA (121.7%)

NVIDIA

AVGO (29.3%)

Broadcom

MSFT (15.3%)

Microsoft

GOOGL (14.1%)

Alphabet

AMZN (12.3%)

Amazon.com

Higher Op Mgn LTM (Value for AMRX: 14.6%)

NVDA (64.0%)

NVIDIA

MSFT (46.8%)

Microsoft

AVGO (44.1%)

Broadcom

GOOGL (32.7%)

Alphabet

AAPL (32.6%)

Apple

Higher CFO/Rev LTM (Value for AMRX: 10.0%)

MSFT (53.5%)

Microsoft

NVDA (49.6%)

NVIDIA

GOOGL (41.3%)

Alphabet

AAPL (31.1%)

Apple

AMZN (20.0%)

Amazon.com

Higher FCF/Rev LTM (Value for AMRX: 6.2%)

NVDA (47.0%)

NVIDIA

AVGO (43.4%)

Broadcom

AAPL (28.6%)

Apple

MSFT (22.9%)

Microsoft

GOOGL (15.2%)

Alphabet

Higher Total Yield (Value for AMRX: 2.4%)

MSFT (5.4%)

Microsoft

GOOGL (3.8%)

Alphabet

AMZN (3.5%)

Amazon.com

AAPL (3.2%)

Apple

NVDA (3.1%)

NVIDIA

Best Bets in Health Care

What You Pay

P/EBIT (Value for AMRX: 12.2x)

RPRX (13.6x)

Royalty Pharma

VEEV (26.2x)

Veeva Systems

DOCS (17.6x)

Doximity

HALO (15.5x)

Halozyme Therapeutics

CPRX (14.3x)

Catalyst Pharmaceuticals

GILD (13.1x)

Gilead Sciences

RMD (14.3x)

ResMed

EXEL (14.0x)

Exelixis

BMY (9.6x)

Bristol-Myers Squibb

AMGN (15.5x)

Amgen

P/E (Value for AMRX: 41.9x)

RPRX (28.0x)

Royalty Pharma

VEEV (26.6x)

Veeva Systems

DOCS (19.3x)

Doximity

HALO (23.2x)

Halozyme Therapeutics

CPRX (17.3x)

Catalyst Pharmaceuticals

GILD (16.7x)

Gilead Sciences

RMD (18.0x)

ResMed

EXEL (16.1x)

Exelixis

BMY (15.1x)

Bristol-Myers Squibb

AMGN (23.4x)

Amgen

What You Get

Rev Chg 3Y Avg (Value for AMRX: 10.3%)

RPRX (1.3%)

Royalty Pharma

VEEV (15.1%)

Veeva Systems

DOCS (15.5%)

Doximity

HALO (29.1%)

Halozyme Therapeutics

CPRX (34.0%)

Catalyst Pharmaceuticals

GILD (3.2%)

Gilead Sciences

RMD (11.3%)

ResMed

EXEL (12.9%)

Exelixis

BMY (1.9%)

Bristol-Myers Squibb

AMGN (12.5%)

Amgen

Rev Chg LTM (Value for AMRX: 7.6%)

RPRX (7.8%)

Royalty Pharma

VEEV (16.2%)

Veeva Systems

DOCS (13.1%)

Doximity

HALO (39.1%)

Halozyme Therapeutics

CPRX (11.7%)

Catalyst Pharmaceuticals

GILD (3.5%)

Gilead Sciences

RMD (10.3%)

ResMed

EXEL (3.3%)

Exelixis

BMY (1.8%)

Bristol-Myers Squibb

AMGN (9.1%)

Amgen

Rev Chg Q (Value for AMRX: 3.9%)

RPRX (11.0%)

Royalty Pharma

VEEV (16.3%)

Veeva Systems

DOCS (5.1%)

Doximity

HALO (42.2%)

Halozyme Therapeutics

CPRX (5.6%)

Catalyst Pharmaceuticals

GILD (4.4%)

Gilead Sciences

RMD (10.8%)

ResMed

EXEL (10.0%)

Exelixis

BMY (2.6%)

Bristol-Myers Squibb

AMGN (5.8%)

Amgen

FCF/Rev 3Y Avg (Value for AMRX: 6.5%)

RPRX (114.4%)

Royalty Pharma

VEEV (46.4%)

Veeva Systems

DOCS (44.5%)

Doximity

HALO (39.9%)

Halozyme Therapeutics

CPRX (34.9%)

Catalyst Pharmaceuticals

GILD (32.5%)

Gilead Sciences

RMD (28.6%)

ResMed

EXEL (27.2%)

Exelixis

BMY (26.5%)

Bristol-Myers Squibb

AMGN (26.4%)

Amgen

[1] Choosing top 10 best bets from each sector quarterly is an alpha producing strategy vs sector benchmark
[2] Historical annualized return of 11%, alpha of 1.9%, and sharpe of 0.52

Latest Trefis Analyses

	Title	Date
0	DASHBOARDS
1	Amneal Pharmaceuticals Stock Jump Looks Great, But How Secure Is That Gain?	10/17/2025
2	AMRX Dip Buy Analysis	07/10/2025
3	Amneal Pharmaceuticals (AMRX) Valuation Ratios Comparison	05/15/2025
4	Amneal Pharmaceuticals Total Shareholder Return (TSR): 30.5% in 2024 and 18.2% 3-yr compounded annual returns (above peer average)	03/07/2025
5	Should You Buy Amneal Pharmaceuticals Stock?	02/28/2025
6	ARTICLES
7	Small Cap Stocks Trading At 52-Week High	11/27/2025

	Title
0	DASHBOARDS
1	Amneal Pharmaceuticals Stock Jump Looks Great, But How Secure Is That Gain?
2	AMRX Dip Buy Analysis
3	Amneal Pharmaceuticals (AMRX) Valuation Ratios Comparison
4	Amneal Pharmaceuticals Total Shareholder Return (TSR): 30.5% in 2024 and 18.2% 3-yr compounded annual returns (above peer average)
5	Should You Buy Amneal Pharmaceuticals Stock?
6	ARTICLES
7	Small Cap Stocks Trading At 52-Week High

Trade Ideas

Select ideas related to AMRX.

null

Recent Active Movers

Top Gainers

Ticker	Company	Category	1D Rtn	YTD Rtn
EWY	iShares MSCI South Korea ETF	Equity	6.9%	125.5%
SOXX	iShares Semiconductor ETF	Equity	6.6%	112.5%
SOXQ	Invesco PHLX Semiconductor ETF	Equity	6.3%	102.2%
SMH	VanEck Semiconductor ETF	Equity	5.8%	83.2%
EEM	iShares MSCI Emerging Markets ETF	Equity	3.3%	29.4%
IEMG	iShares Core MSCI Emerging Markets ETF	Equity	3.1%	27.4%
MTUM	iShares MSCI USA Momentum Factor ETF	Equity	3.1%	35.4%
XLK	State Street Technology Select Sector...	Equity	3.0%	33.1%
ICLN	iShares Global Clean Energy ETF	Equity	3.0%	28.4%
SPMO	Invesco S&P 500 Momentum ETF	Equity	2.8%	34.4%

Top Losers

Ticker	Company	Category	1D Rtn	YTD Rtn
RING	iShares MSCI Global Gold Miners ETF	Equity	-2.4%	-3.1%
IBIT	iShares Bitcoin Trust ETF	Cryptocurrency	-2.0%	-28.3%
PALL	ETFS Physical Palladium Shares	Commodity	-2.0%	-20.1%
FBTC	Fidelity Wise Origin Bitcoin Fund	Cryptocurrency	-2.0%	-28.2%
MISL	First Trust Indxx Aerospace & Defense...	Equity	-1.9%	8.4%
PPLT	ETFS Physical Platinum Shares	Commodity	-1.9%	-17.6%
SLV	iShares Silver Trust	Commodity	-1.8%	-7.6%
XLE	State Street Energy Select Sector SPD...	Equity	-1.6%	21.1%
ITA	iShares U.S. Aerospace & Defense ETF	Equity	-1.6%	11.4%
XOP	State Street SPDR S&P Oil & Gas Explo...	Equity	-1.5%	21.5%

Top Gainers

Ticker	Company	Category	1W Rtn	YTD Rtn
EWY	iShares MSCI South Korea ETF	Equity	10.2%	125.5%
SOXX	iShares Semiconductor ETF	Equity	8.9%	112.5%
SOXQ	Invesco PHLX Semiconductor ETF	Equity	8.8%	102.2%
SMH	VanEck Semiconductor ETF	Equity	8.3%	83.2%
URA	Global X Uranium ETF	Equity	6.6%	11.8%
ARKK	ARK Innovation ETF	Equity	6.3%	4.3%
SPMO	Invesco S&P 500 Momentum ETF	Equity	6.2%	34.4%
MTUM	iShares MSCI USA Momentum Factor ETF	Equity	6.1%	35.4%
XBI	State Street SPDR S&P Biotech ETF	Equity	6.0%	15.4%
RING	iShares MSCI Global Gold Miners ETF	Equity	5.9%	-3.1%

Top Losers

Ticker	Company	Category	1W Rtn	YTD Rtn
NASA	Tema Space Innovators ETF	Equity	-11.3%	24.1%
USO	United States Oil Fund LP	Commodity	-10.8%	66.1%
XOP	State Street SPDR S&P Oil & Gas Explo...	Equity	-6.2%	21.5%
XLE	State Street Energy Select Sector SPD...	Equity	-5.9%	21.1%
FXN	First Trust Energy AlphaDEX Fund	Equity	-5.5%	22.5%
KWEB	KraneShares CSI China Internet ETF	Equity	-5.0%	-25.9%
COMT	iShares GSCI Commodity Dynamic Roll S...	Commodity	-4.7%	26.0%
FXI	iShares China Large-Cap ETF	Equity	-4.6%	-13.0%
PDBC	Invesco Optimum Yield Diversified Com...	Commodity	-4.3%	24.5%
DBC	Invesco DB Commodity Index Tracking Fund	Commodity	-4.2%	23.6%

Top Gainers

Ticker	Company	Category	1M Rtn	YTD Rtn
SOXX	iShares Semiconductor ETF	Equity	28.7%	112.5%
SOXQ	Invesco PHLX Semiconductor ETF	Equity	26.7%	102.2%
EWY	iShares MSCI South Korea ETF	Equity	26.0%	125.5%
SMH	VanEck Semiconductor ETF	Equity	21.3%	83.2%
MTUM	iShares MSCI USA Momentum Factor ETF	Equity	15.7%	35.4%
SPMO	Invesco S&P 500 Momentum ETF	Equity	13.7%	34.4%
VLUE	iShares MSCI USA Value Factor ETF	Equity	12.1%	46.8%
AGIX	KraneShares Artificial Intelligence ETF	Equity	11.3%	30.9%
XBI	State Street SPDR S&P Biotech ETF	Equity	11.0%	15.4%
XLK	State Street Technology Select Sector...	Equity	10.5%	33.1%

Top Losers

Ticker	Company	Category	1M Rtn	YTD Rtn
USO	United States Oil Fund LP	Commodity	-24.9%	66.1%
ETHA	iShares Ethereum Trust ETF	Cryptocurrency	-19.1%	-42.6%
IBIT	iShares Bitcoin Trust ETF	Cryptocurrency	-18.1%	-28.3%
FBTC	Fidelity Wise Origin Bitcoin Fund	Cryptocurrency	-18.0%	-28.2%
COMT	iShares GSCI Commodity Dynamic Roll S...	Commodity	-14.1%	26.0%
XOP	State Street SPDR S&P Oil & Gas Explo...	Equity	-14.1%	21.5%
PPLT	ETFS Physical Platinum Shares	Commodity	-13.8%	-17.6%
DBC	Invesco DB Commodity Index Tracking Fund	Commodity	-12.6%	23.6%
NASA	Tema Space Innovators ETF	Equity	-12.6%	24.1%
PDBC	Invesco Optimum Yield Diversified Com...	Commodity	-12.4%	24.5%

Peer Comparisons

Peers to compare with:

Financials

	AMRX	OPTH	TRLV	LLY	JNJ	MRK	Median
Name	Amneal P.	Optimi H.	Trulieve.	Eli Lilly	Johnson .	Merck
Mkt Price	16.21	5.03	10.10	1,098.57	228.39	113.87	65.04
Mkt Cap	5.1	-	-	982.7	550.1	281.5	415.8
Rev LTM	3,046	0	1,170	72,250	96,362	65,768	34,407
Op Inc LTM	445	-5	149	34,172	25,792	12,970	6,708
FCF LTM	188	-3	224	10,368	17,413	14,115	5,296
FCF 3Y Avg	182	-4	183	1,734	18,074	14,065	958
CFO LTM	306	-3	277	20,480	22,870	17,890	9,098
CFO 3Y Avg	271	-3	267	11,158	23,615	17,842	5,715

Growth & Margins

	AMRX	OPTH	TRLV	LLY	JNJ	MRK	Median
Name	Amneal P.	Optimi H.	Trulieve.	Eli Lilly	Johnson .	Merck
Rev Chg LTM	7.6%	-51.3%	-1.4%	47.4%	7.9%	2.9%	5.3%
Rev Chg 3Y Avg	10.3%	21.6%	-0.6%	37.9%	4.4%	4.4%	7.3%
Rev Chg Q	3.9%	62.5%	-3.7%	55.5%	9.9%	4.9%	7.4%
QoQ Delta Rev Chg LTM	0.9%	19.8%	-0.9%	10.8%	2.3%	1.2%	1.7%
Op Inc Chg LTM	22.3%	-6.5%	79.4%	73.3%	20.7%	-36.4%	21.5%
Op Inc Chg 3Y Avg	30.0%	3.1%	22.8%	67.4%	5.7%	69.7%	26.4%
Op Mgn LTM	14.6%	-2,200.7%	12.7%	47.3%	26.8%	19.7%	17.2%
Op Mgn 3Y Avg	13.0%	-1,777.5%	10.0%	39.7%	25.6%	19.9%	16.4%
QoQ Delta Op Mgn LTM	1.4%	244.9%	0.1%	1.7%	-0.4%	-14.3%	0.8%
CFO/Rev LTM	10.0%	-1,382.7%	23.7%	28.3%	23.7%	27.2%	23.7%
CFO/Rev 3Y Avg	9.7%	-1,212.3%	23.0%	19.2%	26.2%	28.0%	21.1%
FCF/Rev LTM	6.2%	-1,420.9%	19.2%	14.4%	18.1%	21.5%	16.2%
FCF/Rev 3Y Avg	6.5%	-1,311.7%	15.8%	0.3%	20.1%	22.0%	11.1%

Valuation

	AMRX	OPTH	TRLV	LLY	JNJ	MRK	Median
Name	Amneal P.	Optimi H.	Trulieve.	Eli Lilly	Johnson .	Merck
Mkt Cap	5.1	-	-	982.7	550.1	281.5	415.8
P/S	1.7	-	-	13.6	5.7	4.3	5.0
P/Op Inc	11.5	-	-	28.8	21.3	21.7	21.5
P/EBIT	12.2	-	-	27.5	21.2	21.4	21.3
P/E	41.9	-	-	38.9	26.1	31.5	35.2
P/CFO	16.7	-	-	48.0	24.1	15.7	20.4
Total Yield	2.4%	-	-	3.1%	6.1%	6.1%	4.6%
Dividend Yield	0.0%	-	-	0.6%	2.3%	2.9%	1.4%
FCF Yield 3Y Avg	6.8%	-	-	0.2%	4.1%	5.2%	4.7%
D/E	0.5	-	-	0.0	0.1	0.2	0.1
Net D/E	0.5	-	-	0.0	0.1	0.2	0.1

Returns

	AMRX	OPTH	TRLV	LLY	JNJ	MRK	Median
Name	Amneal P.	Optimi H.	Trulieve.	Eli Lilly	Johnson .	Merck
1M Rtn	32.5%	-14.1%	-12.6%	7.8%	0.2%	1.5%	0.8%
3M Rtn	37.0%	-14.1%	-12.6%	21.4%	-2.4%	0.4%	-1.0%
6M Rtn	29.0%	-14.1%	-12.6%	2.9%	11.9%	14.3%	7.4%
12M Rtn	104.2%	-14.1%	-12.6%	40.9%	55.3%	48.4%	44.7%
3Y Rtn	449.5%	-14.1%	-12.6%	148.3%	51.9%	13.3%	32.6%
1M Excs Rtn	35.3%	-16.1%	-14.6%	5.6%	-2.1%	-1.6%	-1.9%
3M Excs Rtn	17.8%	-27.6%	-26.1%	6.4%	-16.9%	-13.1%	-15.0%
6M Excs Rtn	22.9%	-24.4%	-22.9%	-5.7%	0.0%	7.3%	-2.9%
12M Excs Rtn	79.8%	-39.5%	-37.9%	14.5%	28.3%	25.0%	19.7%
3Y Excs Rtn	456.6%	-85.8%	-84.2%	80.1%	-16.6%	-57.4%	-37.0%

FDIC Bank Data

Bank Capital

null

Bank Deposits

null

Bank Assets

null

Bank Loans

null

FDA Approved Drugs Data

Expand for More

					Post-Approval Fwd Returns
FDA App #	Brand Name	Generic Name	Dosage Form	FDA Approval	3M Rtn	6M Rtn	1Y Rtn	2Y Rtn	Total Rtn
ANDA211000	MACITENTAN	macitentan	tablet	6082026	18.2%	18.2%	18.2%	18.2%	18.2%
ANDA219099	ROMIDEPSIN	romidepsin	solution	6022026	28.1%	28.1%	28.1%	28.1%	28.1%
ANDA217734	PHYTONADIONE	phytonadione	injectable	6012026	25.7%	25.7%	25.7%	25.7%	25.7%
ANDA217497	TRETINOIN	tretinoin	gel	5142026	32.5%	32.5%	32.5%	32.5%	32.5%
ANDA219655	SERTRALINE HYDROCHLORIDE	sertraline hydrochloride	capsule	1282026	-8.2%	16.2%	16.2%	16.2%	16.2%
ANDA217287	CUPRIC CHLORIDE	cupric chloride	injectable	1262026	-7.4%	19.5%	19.5%	19.5%	19.5%
ANDA212884	ELTROMBOPAG OLAMINE	eltrombopag olamine	tablet	1142026	-1.5%	22.3%	22.3%	22.3%	22.3%
ANDA217523	SODIUM BICARBONATE	sodium bicarbonate	solution	1132026	1.2%	25.0%	25.0%	25.0%	25.0%
BLA761456	BONCRESA	denosumab-mobz	injectable	12192025	-5.9%	29.0%	29.0%	29.0%	29.0%
BLA761457	OZILTUS	denosumab-mobz	injectable	12192025	-5.9%	29.0%	29.0%	29.0%	29.0%
...

Collapse to Preview

					Post-Approval Fwd Returns
FDA App #	Brand Name	Generic Name	Dosage Form	FDA Approval	3M Rtn	6M Rtn	1Y Rtn	2Y Rtn	Total Rtn
ANDA211000	MACITENTAN	macitentan	tablet	6082026	18.2%	18.2%	18.2%	18.2%	18.2%
ANDA219099	ROMIDEPSIN	romidepsin	solution	6022026	28.1%	28.1%	28.1%	28.1%	28.1%
ANDA217734	PHYTONADIONE	phytonadione	injectable	6012026	25.7%	25.7%	25.7%	25.7%	25.7%
ANDA217497	TRETINOIN	tretinoin	gel	5142026	32.5%	32.5%	32.5%	32.5%	32.5%
ANDA219655	SERTRALINE HYDROCHLORIDE	sertraline hydrochloride	capsule	1282026	-8.2%	16.2%	16.2%	16.2%	16.2%
ANDA217287	CUPRIC CHLORIDE	cupric chloride	injectable	1262026	-7.4%	19.5%	19.5%	19.5%	19.5%
ANDA212884	ELTROMBOPAG OLAMINE	eltrombopag olamine	tablet	1142026	-1.5%	22.3%	22.3%	22.3%	22.3%
ANDA217523	SODIUM BICARBONATE	sodium bicarbonate	solution	1132026	1.2%	25.0%	25.0%	25.0%	25.0%
BLA761456	BONCRESA	denosumab-mobz	injectable	12192025	-5.9%	29.0%	29.0%	29.0%	29.0%
BLA761457	OZILTUS	denosumab-mobz	injectable	12192025	-5.9%	29.0%	29.0%	29.0%	29.0%
ANDA217173	DEFLAZACORT	deflazacort	tablet	12122025	-3.1%	32.7%	32.8%	32.8%	32.8%
ANDA218208	EPINEPHRINE	epinephrine	solution	12082025	11.6%	15.5%	36.6%	36.6%	36.6%
ANDA211909	CYCLOSPORINE	cyclosporine	emulsion	11282025	10.3%	5.2%	29.5%	29.5%	29.5%
ANDA217737	IOHEXOL	iohexol	solution	11132025	27.0%	6.2%	40.7%	40.7%	40.7%
ANDA216601	PHYTONADIONE	phytonadione	injectable	11042025	25.6%	18.1%	42.8%	42.8%	42.8%
ANDA217803	NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE	hydrocortisone	solution/drops	10292025	33.7%	22.7%	55.4%	55.4%	55.4%
ANDA217485	EPINEPHRINE	epinephrine	solution	10142025	33.4%	35.0%	66.8%	66.8%	66.8%
ANDA216097	ISOTRETINOIN	isotretinoin	capsule	10072025	25.4%	18.9%	56.5%	56.5%	56.5%
ANDA218870	LABETALOL HYDROCHLORIDE	labetalol hydrochloride	injectable	10022025	21.2%	20.0%	55.9%	55.9%	55.9%
ANDA217735	NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE	hydrocortisone	suspension/drops	9302025	28.7%	24.2%	61.9%	61.9%	61.9%
ANDA216294	CALCITONIN-SALMON	calcitonin salmon	injectable	9262025	32.8%	21.5%	66.3%	66.3%	66.3%
ANDA217289	BIMATOPROST	bimatoprost	solution/drops	9222025	28.2%	19.2%	62.1%	62.1%	62.1%
ANDA203631	SODIUM OXYBATE	sodium oxybate	solution	9102025	24.3%	29.4%	65.1%	65.1%	65.1%
ANDA218586	RISPERIDONE	risperidone	powder	9022025	25.3%	38.9%	69.2%	69.2%	69.2%
ANDA214100	PENCICLOVIR	penciclovir	cream	8222025	24.6%	51.2%	69.0%	69.0%	69.0%
ANDA218469	SODIUM ACETATE	sodium acetate	solution	8082025	33.1%	70.0%	89.8%	89.8%	89.8%
ANDA218812	PRUCALOPRIDE SUCCINATE	prucalopride succinate	tablet	6242025	21.0%	57.9%	99.4%	99.4%	99.4%
ANDA218256	PREDNISOLONE ACETATE	prednisolone acetate	suspension/drops	6112025	26.2%	56.9%	110.0%	108.4%	108.4%
ANDA218384	SCOPOLAMINE	scopolamine	system	6092025	27.9%	56.0%	93.0%	113.0%	113.0%
ANDA217484	LOTEPREDNOL ETABONATE	loteprednol etabonate	suspension/drops	5202025	25.7%	55.9%	64.8%	118.5%	118.5%
NDA215400	BREKIYA (AUTOINJECTOR)	dihydroergotamine mesylate	solution	5142025	27.9%	61.9%	66.4%	120.5%	120.5%
ANDA217733	PILOCARPINE HYDROCHLORIDE	pilocarpine hydrochloride	solution/drops	4282025	7.2%	34.5%	67.1%	112.7%	112.7%
ANDA215399	INDOMETHACIN	indomethacin	suppository	2242025	-13.7%	11.8%	76.6%	95.3%	95.3%
ANDA215067	MESALAMINE	mesalamine	tablet, delayed release	2182025	-4.7%	19.8%	90.6%	108.1%	108.1%
ANDA216213	LENALIDOMIDE	lenalidomide	capsule	1312025	-3.5%	-5.2%	65.6%	96.2%	96.2%
ANDA218863	EVEROLIMUS	everolimus	tablet, for suspension	1102025	-12.4%	4.5%	62.6%	103.4%	103.4%
ANDA217288	BRIMONIDINE TARTRATE AND TIMOLOL MALEATE	brimonidine tartrate	solution/drops	12302024	7.0%	3.3%	64.5%	107.0%	107.0%
ANDA216345	LOTEPREDNOL ETABONATE	loteprednol etabonate	suspension/drops	12132024	11.7%	-1.0%	55.9%	107.0%	107.0%
ANDA217487	DOXYCYCLINE HYCLATE	doxycycline hyclate	injectable	12042024	1.8%	-18.2%	35.5%	84.0%	84.0%
ANDA206697	EXENATIDE SYNTHETIC	exenatide synthetic	injectable	11192024	-7.7%	-12.1%	36.5%	92.1%	92.1%
ANDA215406	NICARDIPINE HYDROCHLORIDE	nicardipine hydrochloride	injectable	10312024	1.3%	-8.6%	27.7%	91.4%	91.4%
NDA217604	PYRIDOSTIGMINE BROMIDE	pyridostigmine bromide	tablet, extended release	10042024	-9.6%	-14.7%	20.1%	87.4%	87.4%
ANDA205961	PITAVASTATIN CALCIUM	pitavastatin calcium	tablet	8202024	4.2%	-3.8%	16.2%	100.1%	100.1%
ANDA217525	PROPOFOL	propofol	injectable	8152024	13.8%	0.0%	19.5%	104.9%	104.9%
ANDA210962	BROMFENAC SODIUM	bromfenac sodium	solution/drops	7292024	16.3%	20.2%	10.2%	120.8%	120.8%
NDA218343	POTASSIUM PHOSPHATES IN 0.9% SODIUM CHLORIDE	potassium phosphate, dibasic	solution	7262024	12.9%	16.7%	8.3%	117.9%	117.9%
ANDA216055	ESTRADIOL	estradiol	gel	7122024	19.2%	10.8%	15.9%	125.5%	125.5%
ANDA217524	CALCIUM CHLORIDE 10%	calcium chloride	injectable	7082024	24.0%	13.9%	21.0%	137.7%	137.7%
ANDA218618	CABERGOLINE	cabergoline	tablet	6252024	29.8%	20.8%	23.8%	149.4%	149.4%
ANDA216576	AZELASTINE HYDROCHLORIDE	azelastine hydrochloride	spray, metered	6052024	24.7%	29.4%	5.3%	101.9%	138.0%
ANDA216343	TIMOLOL MALEATE	timolol maleate	solution, gel forming/drops	5232024	25.0%	29.2%	11.2%	92.9%	151.7%
ANDA216611	CALCIUM GLUCONATE	calcium gluconate	solution	5102024	14.9%	31.1%	11.3%	98.2%	143.4%
ANDA217992	NALOXONE HYDROCHLORIDE	naloxone hydrochloride	spray, metered	4232024	37.6%	57.4%	35.2%	134.3%	200.2%
ANDA218202	NICARDIPINE HYDROCHLORIDE	nicardipine hydrochloride	capsule	4102024	24.6%	52.3%	22.3%	120.0%	184.4%
ANDA204839	LACOSAMIDE	lacosamide	solution	3272024	5.7%	36.3%	35.0%	93.6%	164.9%
ANDA216600	FOSFOMYCIN TROMETHAMINE	fosfomycin tromethamine	for solution	3252024	10.8%	44.2%	44.3%	107.4%	174.3%
ANDA216501	CIPROFLOXACIN AND DEXAMETHASONE	ciprofloxacin	suspension/drops	3222024	9.6%	43.3%	42.7%	94.9%	167.1%
ANDA216602	FOSCARNET SODIUM	foscarnet sodium	solution	3012024	22.1%	58.3%	58.5%	152.5%	196.3%
ANDA211524	OFLOXACIN	ofloxacin	solution/drops	3012024	22.1%	58.3%	58.5%	152.5%	196.3%
ANDA216348	FLUOROMETHOLONE	fluorometholone	suspension/drops	1092024	0.7%	19.7%	41.7%	132.0%	184.9%
ANDA212493	DARUNAVIR	darunavir	tablet	12082023	6.5%	33.4%	67.0%	140.7%	220.4%
ANDA216502	METHYLPREDNISOLONE ACETATE	methylprednisolone acetate	injectable	11032023	28.7%	57.6%	97.9%	152.2%	277.9%
ANDA209890	DAPSONE	dapsone	gel	10192023	50.4%	51.8%	143.1%	181.0%	359.2%
ANDA217155	TRANEXAMIC ACID	tranexamic acid	solution	10162023	37.8%	41.3%	124.7%	149.5%	313.5%
ANDA216344	POTASSIUM PHOSPHATES	potassium phosphate, dibasic	solution	10102023	40.5%	41.5%	114.3%	154.1%	300.2%
ANDA212704	CARBAMAZEPINE	carbamazepine	tablet, extended release	9222023	37.5%	44.9%	107.6%	134.1%	286.9%
ANDA217174	CALCIUM GLUCONATE IN SODIUM CHLORIDE	calcium gluconate	solution	9052023	20.9%	39.8%	122.3%	150.0%	324.3%
ANDA215572	SPIRONOLACTONE	spironolactone	suspension	9052023	20.9%	39.8%	122.3%	150.0%	324.3%
ANDA202830	LISDEXAMFETAMINE DIMESYLATE	lisdexamfetamine dimesylate	capsule	8252023	15.6%	48.3%	114.3%	145.3%	314.6%
ANDA212357	DOXEPIN HYDROCHLORIDE	doxepin hydrochloride	cream	8162023	22.7%	59.0%	116.1%	158.2%	342.9%
ANDA216278	TIOPRONIN	tiopronin	tablet, delayed release	8152023	16.9%	43.2%	99.7%	140.2%	314.6%
ANDA204382	VALSARTAN AND HYDROCHLOROTHIAZIDE	hydrochlorothiazide	tablet	8112023	6.3%	40.3%	92.7%	115.1%	308.3%
ANDA205941	SAXAGLIPTIN	saxagliptin hydrochloride	tablet	7312023	21.2%	80.0%	125.6%	152.2%	406.6%
ANDA215334	PLERIXAFOR	plerixafor	solution	7242023	2.4%	66.8%	126.5%	146.0%	394.2%
ANDA207480	OLMESARTAN MEDOXOMIL	olmesartan medoxomil	tablet	7112023	32.8%	86.6%	132.8%	175.1%	431.5%
ANDA215338	VANCOMYCIN HYDROCHLORIDE	vancomycin hydrochloride	for solution	6232023	45.5%	100.0%	130.9%	171.5%	462.8%
ANDA217460	MOMETASONE FUROATE	mometasone furoate	spray, metered	6142023	51.7%	76.4%	162.2%	190.3%	507.1%
ANDA215035	AMLODIPINE BENZOATE	amlodipine benzoate	suspension	6132023	55.0%	79.8%	175.6%	208.5%	528.3%
ANDA215397	MEDROXYPROGESTERONE ACETATE	medroxyprogesterone acetate	injectable	6072023	50.4%	85.0%	172.0%	209.8%	558.9%
ANDA212701	DAPSONE	dapsone	gel	5312023	75.2%	85.9%	189.7%	212.8%	592.7%
ANDA217665	METRONIDAZOLE IN PLASTIC CONTAINER	metronidazole	injectable	5242023	79.4%	95.2%	182.5%	214.0%	611.0%
ANDA216604	DEXMEDETOMIDINE HYDROCHLORIDE	dexmedetomidine hydrochloride	injectable	5152023	94.6%	111.9%	239.1%	263.9%	702.5%
ANDA216598	PROCHLORPERAZINE MALEATE	prochlorperazine maleate	tablet	4172023	92.7%	137.6%	230.3%	335.2%	882.4%
ANDA216346	NELARABINE	nelarabine	injectable	4042023	124.3%	219.1%	342.6%	474.3%	1,091.9%
ANDA216276	THEOPHYLLINE	theophylline	tablet, extended release	3202023	89.5%	206.3%	343.4%	510.5%	1,033.6%
ANDA216605	ROPIVACAINE HYDROCHLORIDE	ropivacaine hydrochloride	solution	3082023	46.4%	120.2%	216.1%	429.8%	864.9%
ANDA216597	MAGNESIUM SULFATE IN PLASTIC CONTAINER	magnesium sulfate	injectable	2152023	-17.1%	45.8%	134.7%	208.0%	545.8%
ANDA213562	BREXPIPRAZOLE	brexpiprazole	tablet	1312023	-15.5%	44.1%	143.2%	290.0%	636.8%
ANDA205002	FESOTERODINE FUMARATE	fesoterodine fumarate	tablet, extended release	1042023	-38.2%	27.2%	171.9%	260.4%	647.0%
ANDA216626	POSACONAZOLE	posaconazole	tablet, delayed release	12222022	-39.9%	32.6%	164.2%	256.9%	643.6%
ANDA216603	ESMOLOL HYDROCHLORIDE	esmolol hydrochloride	injectable	12132022	-42.6%	3.6%	89.2%	218.1%	551.0%
ANDA214192	PROCHLORPERAZINE EDISYLATE	prochlorperazine edisylate	injectable	11282022	-10.7%	-6.2%	75.2%	245.0%	569.8%
ANDA214811	MUPIROCIN	mupirocin calcium	cream	11152022	7.4%	-11.7%	95.2%	291.3%	604.8%
ANDA215219	CLINDAMYCIN PHOSPHATE	clindamycin phosphate	gel	11032022	14.9%	-11.5%	106.2%	308.2%	679.3%
ANDA215336	LEUPROLIDE ACETATE	leuprolide acetate	solution	10282022	-8.5%	-17.5%	61.1%	259.0%	592.7%
ANDA216715	PREDNISOLONE SODIUM PHOSPHATE	prednisolone sodium phosphate	solution	10252022	-5.4%	-23.7%	75.0%	271.0%	623.7%
ANDA216599	DOXYCYCLINE HYCLATE	doxycycline hyclate	tablet	10242022	-1.8%	-19.4%	84.3%	283.4%	647.0%
ANDA215333	GLYCOPYRROLATE	glycopyrrolate	injectable	10212022	-0.5%	-23.1%	63.7%	304.7%	664.6%
ANDA216295	DEXAMETHASONE	dexamethasone	tablet	9082022	-0.4%	-28.9%	60.4%	257.0%	589.8%
ANDA208198	DICLOFENAC SODIUM	diclofenac sodium	solution	8182022	-21.8%	-15.0%	33.2%	187.1%	478.9%
ANDA215104	IPRATROPIUM BROMIDE	ipratropium bromide	spray, metered	8162022	-23.3%	-17.7%	22.0%	163.7%	440.3%
ANDA215105	IPRATROPIUM BROMIDE	ipratropium bromide	spray, metered	8162022	-23.3%	-17.7%	22.0%	163.7%	440.3%
ANDA212944	VASOPRESSIN	vasopressin	solution	8052022	-33.3%	-23.6%	29.2%	119.8%	409.7%
ANDA214668	CLINDAMYCIN PHOSPHATE	clindamycin phosphate	gel	8052022	-33.3%	-23.6%	29.2%	119.8%	409.7%
ANDA210047	PEMETREXED DISODIUM	pemetrexed disodium	powder	8042022	-39.9%	-30.9%	18.8%	102.0%	368.5%
ANDA216427	FAMOTIDINE	famotidine	for suspension	8042022	-39.9%	-30.9%	18.8%	102.0%	368.5%
ANDA214752	ATROPINE SULFATE	atropine sulfate	solution/drops	7142022	-36.5%	-29.2%	-3.8%	128.3%	414.6%
ANDA212894	ENALAPRIL MALEATE	enalapril maleate	solution	6292022	-38.0%	-40.7%	-13.6%	91.3%	388.3%
ANDA210042	VIGABATRIN	vigabatrin	tablet	6222022	-31.7%	-28.5%	-6.5%	115.2%	424.6%
ANDA214293	ESTRADIOL AND PROGESTERONE	estradiol	capsule	5162022	-7.0%	-30.9%	-40.8%	100.3%	372.6%
ANDA215398	BEXAROTENE	bexarotene	gel	4272022	-8.0%	-40.3%	-53.0%	51.7%	318.9%
ANDA215576	SUCRALFATE	sucralfate	tablet	4152022	-24.0%	-52.4%	-67.0%	34.0%	293.4%
BLA761231	ALYMSYS	bevacizumab-maly	injectable	4132022	-27.0%	-53.2%	-68.0%	27.2%	273.5%
ANDA212570	PIRFENIDONE	pirfenidone	tablet	3252022	-22.9%	-49.4%	-68.0%	46.3%	290.6%
ANDA204857	LACOSAMIDE	lacosamide	tablet	3172022	-27.5%	-43.4%	-65.5%	32.5%	290.6%
ANDA215456	THIOTHIXENE	thiothixene	capsule	2282022	-23.6%	-45.9%	-54.5%	21.9%	257.8%
ANDA211549	AZACITIDINE	azacitidine	powder	2032022	-26.2%	-28.1%	-49.5%	14.8%	237.0%
ANDA215337	CARBOPROST TROMETHAMINE	carboprost tromethamine	injectable	1272022	-7.9%	-16.3%	-50.1%	28.0%	277.9%
ANDA215342	ATROPINE SULFATE	atropine sulfate	solution	1262022	-10.6%	-17.8%	-50.6%	26.8%	274.4%
ANDA214105	DIHYDROERGOTAMINE MESYLATE	dihydroergotamine mesylate	spray, metered	1042022	-16.0%	-32.1%	-55.6%	20.7%	231.5%
ANDA212569	PIRFENIDONE	pirfenidone	capsule	1032022	-12.8%	-30.7%	-56.5%	20.8%	234.2%
ANDA209450	LUBIPROSTONE	lubiprostone	capsule	11302021	6.5%	-13.2%	-38.8%	3.1%	287.8%
ANDA211526	DIFLUPREDNATE	difluprednate	emulsion	11172021	1.7%	-27.0%	-54.1%	-5.0%	239.8%
ANDA214871	MYCOPHENOLATE MOFETIL	mycophenolate mofetil	for suspension	11022021	-20.6%	-31.1%	-63.7%	-28.7%	178.5%
ANDA215555	CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDE	chlordiazepoxide hydrochloride	capsule	10252021	-21.8%	-32.0%	-60.6%	-31.1%	184.9%
ANDA215106	DEXAMETHASONE	dexamethasone	tablet	10142021	-19.5%	-28.1%	-65.8%	-33.0%	182.9%
ANDA207481	METHYLPREDNISOLONE	methylprednisolone	tablet	9212021	-7.2%	-19.7%	-58.1%	-15.1%	222.3%
ANDA214292	NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE	ethinyl estradiol	capsule	7202021	20.6%	-4.3%	-29.8%	-24.5%	244.9%
ANDA212991	TOBRAMYCIN AND DEXAMETHASONE	dexamethasone	suspension/drops	7152021	31.4%	5.7%	-28.2%	-30.5%	271.8%
ANDA211782	APREMILAST	apremilast	tablet	6302021	7.4%	-4.1%	-37.9%	-39.5%	216.6%
ANDA214895	CLOBETASOL PROPIONATE	clobetasol propionate	shampoo	6142021	-11.3%	-29.9%	-46.7%	-53.6%	181.4%
ANDA214196	ETRAVIRINE	etravirine	tablet	6142021	-11.3%	-29.9%	-46.7%	-53.6%	181.4%
ANDA207690	RANOLAZINE	ranolazine	tablet, extended release	3112021	-2.0%	-16.1%	-32.9%	-75.1%	164.0%
ANDA211374	MYCOPHENOLATE MOFETIL HYDROCHLORIDE	mycophenolate mofetil hydrochloride	injectable	3052021	10.3%	9.5%	-18.4%	-61.2%	227.5%
ANDA213950	ETHINYL ESTRADIOL AND NORELGESTROMIN	ethinyl estradiol	film, extended release	2252021	14.3%	5.9%	-6.1%	-55.4%	231.5%
ANDA214194	DEFERASIROX	deferasirox	granule	2092021	-7.2%	-13.1%	-16.9%	-60.2%	176.6%
ANDA210739	ARSENIC TRIOXIDE	arsenic trioxide	injectable	1252021	21.0%	-0.4%	-7.4%	-55.7%	234.2%
ANDA212256	TAVABOROLE	tavaborole	solution	11252020	28.1%	42.0%	16.1%	-39.9%	307.3%
ANDA208766	ACYCLOVIR	acyclovir	cream	11092020	41.1%	26.7%	27.4%	-46.3%	286.9%
ANDA212568	PHENOXYBENZAMINE HYDROCHLORIDE	phenoxybenzamine hydrochloride	capsule	10272020	6.0%	22.3%	14.3%	-52.2%	247.1%
ANDA211396	ESTRADIOL	estradiol	film, extended release	9282020	16.4%	76.1%	43.4%	-46.5%	321.0%
ANDA210402	DIMETHYL FUMARATE	dimethyl fumarate	capsule, delayed release	9242020	16.0%	78.3%	39.0%	-45.0%	324.3%
ANDA214193	PILOCARPINE HYDROCHLORIDE	pilocarpine hydrochloride	solution/drops	9212020	2.1%	74.1%	18.6%	-50.2%	282.3%
ANDA205107	MONTELUKAST SODIUM	montelukast sodium	tablet, chewable	9042020	15.3%	35.6%	48.5%	-39.7%	344.1%
ANDA206463	LIDOCAINE	lidocaine	patch	8242020	2.8%	34.7%	39.2%	-35.2%	307.3%
ANDA212705	NAPROXEN	naproxen	suspension	7312020	-3.9%	11.1%	13.9%	-18.2%	274.4%
ANDA213734	METYROSINE	metyrosine	capsule	7242020	21.4%	15.9%	12.6%	-26.3%	277.9%
ANDA213647	FLUPHENAZINE HYDROCHLORIDE	fluphenazine hydrochloride	tablet	7092020	3.9%	13.8%	7.8%	-24.3%	271.8%
ANDA213386	PREDNISONE	prednisone	tablet	6242020	-16.8%	-8.1%	12.2%	-33.6%	236.3%
ANDA213385	PREDNISONE	prednisone	tablet	6162020	-14.8%	-2.3%	21.7%	-36.5%	242.0%
ANDA209717	ATAZANAVIR SULFATE	atazanavir sulfate	capsule	6012020	-13.7%	-17.0%	19.5%	-22.3%	240.5%
ANDA207551	DEXMEDETOMIDINE HYDROCHLORIDE	dexmedetomidine hydrochloride	injectable	5202020	-7.7%	-10.1%	24.7%	-23.2%	254.7%
ANDA212861	POTASSIUM CHLORIDE	potassium chloride	tablet, extended release	5082020	24.2%	16.3%	46.5%	-4.2%	356.6%
NDA212489	ONGENTYS	opicapone	capsule	4242020	34.1%	62.8%	77.5%	22.2%	406.6%
ANDA211586	BUPRENORPHINE	buprenorphine	film, extended release	4142020	39.0%	42.0%	73.2%	22.6%	382.4%
ANDA210901	OLOPATADINE HYDROCHLORIDE	olopatadine hydrochloride	spray, metered	1282020	-22.8%	-10.9%	2.8%	-8.7%	244.9%
ANDA212702	PYRIDOSTIGMINE BROMIDE	pyridostigmine bromide	syrup	1102020	-26.4%	3.1%	6.0%	2.7%	259.4%
ANDA210509	MESALAMINE	mesalamine	suppository	1022020	-36.1%	-5.2%	-4.2%	0.4%	239.8%
ANDA210830	ELURYNG	ethinyl estradiol	ring	12112019	-6.6%	45.4%	20.4%	16.1%	365.8%
ANDA209356	SUCRALFATE	sucralfate	suspension	12022019	3.6%	24.0%	5.5%	6.8%	322.1%
ANDA211092	SILDENAFIL CITRATE	sildenafil citrate	for suspension	11272019	17.4%	50.9%	21.3%	29.6%	394.2%
ANDA212492	AMINOCAPROIC ACID	aminocaproic acid	tablet	11262019	56.6%	63.5%	30.9%	52.0%	433.2%
ANDA211204	ERYTHROMYCIN ETHYLSUCCINATE	erythromycin ethylsuccinate	granule	11012019	30.9%	-2.6%	21.3%	60.1%	372.6%
ANDA212932	EPHEDRINE SULFATE	ephedrine sulfate	solution	10232019	67.1%	3.9%	76.5%	84.7%	428.0%
ANDA211212	SIROLIMUS	sirolimus	solution	10182019	70.6%	13.4%	72.2%	88.6%	442.1%
ANDA204707	PALIPERIDONE	paliperidone	tablet, extended release	9232019	40.5%	16.2%	32.6%	53.7%	394.2%
ANDA211525	OFLOXACIN	ofloxacin	solution/drops	8302019	47.5%	51.0%	58.0%	107.5%	535.7%
ANDA212780	AMINOCAPROIC ACID	aminocaproic acid	solution	8232019	23.8%	84.5%	64.3%	92.5%	543.3%
ANDA209743	PREGABALIN	pregabalin	capsule	7192019	-12.1%	50.0%	42.9%	26.8%	376.8%
ANDA210954	ERYTHROMYCIN	erythromycin	tablet, delayed release	7022019	-59.0%	-30.2%	-32.9%	-23.6%	134.6%
ANDA207204	CHLORTHALIDONE	chlorthalidone	tablet	7012019	-59.2%	-36.6%	-33.0%	-27.9%	128.3%
ANDA209716	ESOMEPRAZOLE MAGNESIUM	esomeprazole magnesium	capsule, delayed release	6052019	-66.8%	-49.2%	-41.4%	-31.5%	103.4%
ANDA210902	POTASSIUM CHLORIDE	potassium chloride	for solution	5232019	-67.5%	-63.2%	-43.2%	-30.7%	96.5%
ANDA210043	METHYLPREDNISOLONE ACETATE	methylprednisolone acetate	injectable	5202019	-65.4%	-65.7%	-45.2%	-30.3%	96.2%
ANDA209719	SOLIFENACIN SUCCINATE	solifenacin succinate	tablet	5202019	-65.4%	-65.7%	-45.2%	-30.3%	96.2%
ANDA209742	BOSENTAN	bosentan	tablet	4262019	-70.6%	-72.5%	-74.3%	-54.3%	30.4%
ANDA209647	ESOMEPRAZOLE MAGNESIUM	esomeprazole magnesium	capsule, delayed rel pellets	4102019	-68.2%	-79.4%	-75.8%	-56.6%	18.1%
ANDA207373	TESTOSTERONE	testosterone	gel, metered	4102019	-68.2%	-79.4%	-75.8%	-56.6%	18.1%
ANDA209744	TADALAFIL	tadalafil	tablet	3262019	-54.1%	-77.3%	-75.7%	-52.6%	12.9%
ANDA206165	NAFTIFINE HYDROCHLORIDE	naftifine hydrochloride	gel	3202019	-52.5%	-77.2%	-77.7%	-49.9%	13.4%
ANDA210044	FULVESTRANT	fulvestrant	solution	3042019	-38.5%	-80.3%	-70.5%	-62.2%	25.4%
ANDA210831	LEVOTHYROXINE SODIUM	levothyroxine sodium	tablet	2192019	-34.8%	-80.2%	-65.1%	-59.8%	15.7%
ANDA207495	IMATINIB MESYLATE	imatinib mesylate	tablet	2082019	-19.0%	-77.4%	-62.3%	-59.6%	26.0%
ANDA210619	TRIENTINE HYDROCHLORIDE	trientine hydrochloride	capsule	2082019	-19.0%	-77.4%	-62.3%	-59.6%	26.0%
ANDA211293	ESTRADIOL	estradiol	system	2052019	2.7%	-77.2%	-62.9%	-61.1%	23.8%
ANDA210790	LEVOMILNACIPRAN HYDROCHLORIDE	levomilnacipran hydrochloride	capsule, extended release	2042019	8.5%	-76.7%	-64.2%	-62.0%	25.2%
ANDA208531	TICAGRELOR	ticagrelor	tablet	1232019	-0.2%	-70.7%	-59.2%	-60.2%	29.8%
ANDA207308	RIVASTIGMINE	rivastigmine	film, extended release	1082019	-0.8%	-50.8%	-67.3%	-64.1%	17.2%
ANDA208327	ABIRATERONE ACETATE	abiraterone acetate	tablet	1072019	-5.6%	-54.6%	-68.4%	-67.4%	9.3%
ANDA208002	LURASIDONE HYDROCHLORIDE	lurasidone hydrochloride	tablet	1032019	5.0%	-48.7%	-65.2%	-66.3%	19.4%
ANDA206421	EXEMESTANE	exemestane	tablet	12282018	2.3%	-48.2%	-67.4%	-68.0%	17.0%
ANDA211256	CLOBETASOL PROPIONATE	clobetasol propionate	cream	12262018	-1.4%	-52.5%	-68.3%	-69.3%	12.3%
ANDA210839	NOREPINEPHRINE BITARTRATE	norepinephrine bitartrate	injectable	12172018	-11.5%	-57.4%	-68.3%	-71.7%	0.0%
ANDA077215	AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE	amlodipine besylate	capsule	12072018	-31.4%	-55.9%	-78.8%	-75.7%	-6.6%
ANDA209745	SILODOSIN	silodosin	capsule	12032018	-28.9%	-56.3%	-77.8%	-77.8%	-10.9%
ANDA207497	LAMOTRIGINE	lamotrigine	tablet, extended release	11302018	-23.8%	-57.4%	-78.8%	-77.0%	-8.5%
ANDA211432	SUCCINYLCHOLINE CHLORIDE	succinylcholine chloride	injectable	11162018	-25.8%	-53.7%	-85.1%	-77.6%	-12.4%
ANDA211292	FROVATRIPTAN SUCCINATE	frovatriptan succinate	tablet	11062018	-31.4%	-29.6%	-85.5%	-74.2%	-15.1%
ANDA209692	GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE	dextromethorphan hydrobromide	tablet, extended release	11012018	-37.6%	-32.3%	-82.6%	-78.9%	-17.6%
ANDA208632	CLOMIPRAMINE HYDROCHLORIDE	clomipramine hydrochloride	capsule	10312018	-35.1%	-31.3%	-83.3%	-77.5%	-12.1%
ANDA211405	QUETIAPINE FUMARATE	quetiapine fumarate	tablet, extended release	10262018	-35.0%	-32.3%	-81.4%	-71.6%	-11.7%
ANDA209726	NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE	diphenhydramine hydrochloride	tablet	10232018	-36.0%	-33.9%	-84.2%	-72.1%	-16.7%
ANDA210039	CLOBAZAM	clobazam	suspension	10222018	-34.6%	-32.4%	-84.1%	-72.3%	-14.6%
ANDA209718	CLOBAZAM	clobazam	tablet	10222018	-34.6%	-32.4%	-84.1%	-72.3%	-14.6%
ANDA210576	ISOPROTERENOL HYDROCHLORIDE	isoproterenol hydrochloride	injectable	10172018	-32.7%	-32.3%	-83.7%	-72.1%	-12.2%
ANDA208850	ROSUVASTATIN CALCIUM	rosuvastatin calcium	tablet	10162018	-29.9%	-25.9%	-84.3%	-72.7%	-12.2%
ANDA211301	URSODIOL	ursodiol	capsule	10162018	-29.9%	-25.9%	-84.3%	-72.7%	-12.2%
ANDA211229	CARMUSTINE	carmustine	injectable	10162018	-29.9%	-25.9%	-84.3%	-72.7%	-12.2%
ANDA209613	TERIFLUNOMIDE	teriflunomide	tablet	9282018	-37.6%	-36.1%	-85.6%	-82.2%	-26.9%
ANDA211139	AMPHETAMINE SULFATE	amphetamine sulfate	tablet	9262018	-34.6%	-35.5%	-85.2%	-82.1%	-26.6%
ANDA210674	TETRACYCLINE HYDROCHLORIDE	tetracycline hydrochloride	capsule	9182018	-32.2%	-38.6%	-86.1%	-81.8%	-30.9%
ANDA208890	RITONAVIR	ritonavir	tablet	9172018	-28.9%	-37.1%	-86.1%	-81.5%	-28.9%
ANDA209755	CHLORPROMAZINE HYDROCHLORIDE	chlorpromazine hydrochloride	tablet	9102018	-26.9%	-48.6%	-84.9%	-84.0%	-29.8%
ANDA211483	METHYLERGONOVINE MALEATE	methylergonovine maleate	tablet	9102018	-26.9%	-48.6%	-84.9%	-84.0%	-29.8%
ANDA210105	BEXAROTENE	bexarotene	capsule	9042018	-24.8%	-46.0%	-88.7%	-84.1%	-31.0%
ANDA208689	DEXAMETHASONE SODIUM PHOSPHATE	dexamethasone sodium phosphate	injectable	8222018	-22.4%	-43.9%	-88.8%	-82.8%	-32.5%
ANDA208690	DEXAMETHASONE SODIUM PHOSPHATE PRESERVATIVE FREE	dexamethasone sodium phosphate	injectable	8222018	-22.4%	-43.9%	-88.8%	-82.8%	-32.5%
ANDA209721	EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE	emtricitabine	tablet	8222018	-22.4%	-43.9%	-88.8%	-82.8%	-32.5%
ANDA210554	FLUOCINONIDE	fluocinonide	cream	8212018	-21.7%	-41.0%	-88.3%	-82.5%	-31.8%
ANDA210551	CLOBETASOL PROPIONATE	clobetasol propionate	ointment	8212018	-21.7%	-41.0%	-88.3%	-82.5%	-31.8%
NDA211158	TIGECYCLINE	tigecycline	powder	8022018	2.4%	-36.0%	-83.1%	-77.4%	-15.6%
ANDA210041	POTASSIUM CHLORIDE	potassium chloride	solution	7192018	0.1%	-32.4%	-81.6%	-73.7%	-12.3%
ANDA205666	AZITHROMYCIN	azithromycin	for suspension	7192018	0.1%	-32.4%	-81.6%	-73.7%	-12.3%
ANDA211078	PHENYLEPHRINE HYDROCHLORIDE	phenylephrine hydrochloride	solution	7192018	0.1%	-32.4%	-81.6%	-73.7%	-12.3%
ANDA210994	VERAPAMIL HYDROCHLORIDE	verapamil hydrochloride	solution	7132018	0.3%	-28.8%	-80.3%	-75.2%	-13.6%
ANDA207342	GUAIFENESIN	guaifenesin	tablet, extended release	7112018	5.5%	-26.1%	-77.6%	-74.3%	-10.3%
ANDA211079	PHENYLEPHRINE HYDROCHLORIDE	phenylephrine hydrochloride	solution	7052018	20.8%	-19.6%	-60.6%	-73.3%	-4.1%
ANDA202023	SILDENAFIL CITRATE	sildenafil citrate	tablet	6272018	37.3%	-10.3%	-55.9%	-71.5%	0.8%
ANDA205913	PRASUGREL	prasugrel hydrochloride	tablet	6192018	24.5%	-15.6%	-64.0%	-73.7%	-14.0%
ANDA210051	NEOSTIGMINE METHYLSULFATE	neostigmine methylsulfate	solution	6152018	19.9%	-17.7%	-64.9%	-77.1%	-17.2%
ANDA208834	ETODOLAC	etodolac	tablet	6072018	24.9%	-8.3%	-59.7%	-73.9%	-14.5%
ANDA211111	FLUOCINONIDE	fluocinonide	cream	6042018	22.0%	-4.0%	-57.2%	-74.7%	-14.4%
ANDA208833	CELECOXIB	celecoxib	capsule	5312018	13.9%	-4.4%	-61.8%	-75.3%	-17.9%
ANDA210046	CYCLOPHOSPHAMIDE	cyclophosphamide	injectable	5252018	26.1%	0.8%	-54.7%	-74.4%	-11.4%
ANDA208804	ALBUTEROL SULFATE	albuterol sulfate	tablet	5212018	45.3%	12.1%	-45.3%	-72.6%	-2.9%
ANDA210577	HYDROXYCHLOROQUINE SULFATE	hydroxychloroquine sulfate	tablet	5152018	46.8%	27.7%	-42.3%	-72.8%	7.4%
ANDA209373	PHYTONADIONE	phytonadione	tablet	5112018	38.1%	34.4%	-29.1%	-75.9%	10.3%
ANDA208805	ETHACRYNIC ACID	ethacrynic acid	tablet	5082018	37.9%	29.8%	-10.7%	-75.9%	10.2%
ANDA204740	IRBESARTAN	irbesartan	tablet	4172018	-5.1%	-6.2%	-36.5%	-83.6%	-17.7%
ANDA209950	FENOFIBRATE	fenofibrate	tablet	3192018
ANDA210155	VIGABATRIN	vigabatrin	for solution	3132018
ANDA209720	ERYTHROMYCIN	erythromycin	tablet	3092018
ANDA210186	OSELTAMIVIR PHOSPHATE	oseltamivir phosphate	for suspension	2272018
ANDA209990	NYSTATIN AND TRIAMCINOLONE ACETONIDE	nystatin	cream	2152018
ANDA209951	FENOFIBRATE	fenofibrate	tablet	2092018
ANDA207515	METHYLPHENIDATE HYDROCHLORIDE	methylphenidate hydrochloride	tablet, extended release	2012018
ANDA206698	ARGATROBAN	argatroban	injectable	1262018
ANDA209640	DOCETAXEL	docetaxel	injectable	1192018
ANDA210040	METHOTREXATE SODIUM	methotrexate sodium	tablet	12222017
ANDA209580	BUSULFAN	busulfan	injectable	12182017
ANDA208199	AZELASTINE HYDROCHLORIDE	azelastine hydrochloride	spray, metered	12152017
ANDA207550	TRIAMCINOLONE ACETONIDE	triamcinolone acetonide	injectable	12112017
ANDA208181	TIAGABINE HYDROCHLORIDE	tiagabine hydrochloride	tablet	12082017
ANDA207288	SEVELAMER CARBONATE	sevelamer carbonate	tablet	11282017
ANDA208831	EZETIMIBE AND SIMVASTATIN	ezetimibe	tablet	11212017
ANDA210052	CLONIDINE HYDROCHLORIDE	clonidine hydrochloride	tablet, extended release	11202017
ANDA209493	SODIUM NITROPRUSSIDE	sodium nitroprusside	injectable	11072017
ANDA208857	CLOFARABINE	clofarabine	solution	11062017
ANDA210174	ZOLEDRONIC ACID	zoledronic acid	injectable	10272017
ANDA209724	BUMETANIDE	bumetanide	tablet	10182017
ANDA209372	DOXYCYCLINE HYCLATE	doxycycline hyclate	tablet	10062017
ANDA207792	ISOTRETINOIN	isotretinoin	capsule	9292017
ANDA207514	NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE	ethinyl estradiol	tablet	9112017
ANDA207548	LEVOLEUCOVORIN CALCIUM	levoleucovorin calcium	solution	9082017
ANDA207724	PROGESTERONE	progesterone	capsule	9072017
ANDA204660	AZELASTINE HYDROCHLORIDE	azelastine hydrochloride	spray, metered	8282017
ANDA206200	BUDESONIDE	budesonide	capsule, delayed release	7312017
ANDA203133	DEXTROMETHORPHAN POLISTIREX	dextromethorphan polistirex	suspension, extended release	7282017
ANDA207482	DOXEPIN HYDROCHLORIDE	doxepin hydrochloride	capsule	6282017
ANDA206869	HYDROCODONE BITARTRATE AND ACETAMINOPHEN	acetaminophen	tablet	6232017
ANDA208973	GLYCOPYRROLATE	glycopyrrolate	injectable	6152017
ANDA203289	CALCITRIOL	calcitriol	capsule	6142017
ANDA208803	EZETIMIBE	ezetimibe	tablet	6122017
ANDA208832	NADOLOL	nadolol	tablet	6022017
ANDA208829	BUSPIRONE HYDROCHLORIDE	buspirone hydrochloride	tablet	5242017
ANDA208974	DOXERCALCIFEROL	doxercalciferol	injectable	5242017
ANDA208975	DOXERCALCIFEROL	doxercalciferol	injectable	5242017
ANDA205619	ESCITALOPRAM OXALATE	escitalopram oxalate	tablet	5172017
ANDA209093	OSELTAMIVIR PHOSPHATE	oseltamivir phosphate	capsule	5172017
ANDA207372	NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)	nitrofurantoin	capsule	5152017
ANDA208633	OXAPROZIN	oxaprozin	tablet	5042017
ANDA206960	NAFTIFINE HYDROCHLORIDE	naftifine hydrochloride	cream	4102017
ANDA207989	MOMETASONE FUROATE	mometasone furoate	spray, metered	4032017
ANDA206699	PARICALCITOL	paricalcitol	solution	3092017
ANDA204741	CAPECITABINE	capecitabine	tablet	2282017
ANDA208840	TRANEXAMIC ACID	tranexamic acid	injectable	2282017
ANDA208888	DOXORUBICIN HYDROCHLORIDE	doxorubicin hydrochloride	injectable	2172017
ANDA207547	LEVOLEUCOVORIN CALCIUM	levoleucovorin calcium	powder	2132017
ANDA208328	MEMANTINE HYDROCHLORIDE AND DONEPEZIL HYDROCHLORIDE	donepezil hydrochloride	capsule, extended release	1272017
ANDA206647	ALOSETRON HYDROCHLORIDE	alosetron hydrochloride	tablet	12222016
ANDA207137	HYDROCODONE BITARTRATE AND ACETAMINOPHEN	acetaminophen	tablet	11292016
ANDA203995	DICLOFENAC SODIUM AND MISOPROSTOL	diclofenac sodium	tablet, delayed release	11252016
ANDA207549	METHYLPREDNISOLONE SODIUM SUCCINATE	methylprednisolone sodium succinate	injectable	11092016
ANDA205825	MEMANTINE HYDROCHLORIDE	memantine hydrochloride	capsule, extended release	10122016
ANDA204711	COLCHICINE	colchicine	tablet	9282016
ANDA205080	ITRACONAZOLE	itraconazole	capsule	9262016
ANDA206116	DICLOFENAC SODIUM	diclofenac sodium	solution	9022016
ANDA207552	FUROSEMIDE	furosemide	injectable	7202016
ANDA207289	DOXYCYCLINE HYCLATE	doxycycline hyclate	capsule	6272016
ANDA204838	ARIPIPRAZOLE	aripiprazole	tablet	6172016
ANDA203482	TEMAZEPAM	temazepam	capsule	5232016
ANDA091193	BACLOFEN	baclofen	injectable	5032016
ANDA205081	MILNACIPRAN HYDROCHLORIDE	milnacipran hydrochloride	tablet	4222016
ANDA205034	VORICONAZOLE	voriconazole	for suspension	4132016
ANDA205883	MEROPENEM	meropenem	injectable	4122016
ANDA208206	RALOXIFENE HYDROCHLORIDE	raloxifene hydrochloride	tablet	4082016
ANDA208077	DICLOFENAC SODIUM	diclofenac sodium	gel	3182016
ANDA208105	DESIPRAMINE HYDROCHLORIDE	desipramine hydrochloride	tablet	3172016
ANDA206392	ASPIRIN AND DIPYRIDAMOLE	aspirin	capsule, extended release	3082016
ANDA205119	PANTOPRAZOLE SODIUM	pantoprazole sodium	tablet, delayed release	1262016
ANDA204327	PARICALCITOL	paricalcitol	capsule	1132016
ANDA204011	VALSARTAN	valsartan	tablet	1112016
ANDA204536	LINEZOLID	linezolid	tablet	12212015
ANDA204178	NIACIN	niacin	tablet, extended release	12112015
ANDA204940	OMEGA-3-ACID ETHYL ESTERS	omega-3-acid ethyl esters	capsule	11272015
ANDA204010	OXYBUTYNIN CHLORIDE	oxybutynin chloride	tablet, extended release	11232015
ANDA203118	DUTASTERIDE	dutasteride	capsule	11202015
ANDA206652	ENTECAVIR	entecavir	tablet	11122015
ANDA205573	ITRACONAZOLE	itraconazole	solution	10302015
ANDA204415	TELMISARTAN	telmisartan	tablet	9082015
ANDA204604	MONTELUKAST SODIUM	montelukast sodium	tablet	9042015
ANDA200963	PROMETHAZINE HYDROCHLORIDE,PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE	codeine phosphate	syrup	8262015
ANDA203906	ARIPIPRAZOLE	aripiprazole	solution	8142015
ANDA206297	LIDOCAINE	lidocaine	ointment	8072015
ANDA204179	RABEPRAZOLE SODIUM	rabeprazole sodium	tablet, delayed release	7312015
ANDA203578	NIACIN	niacin	tablet, extended release	7242015
ANDA203729	QUININE SULFATE	quinine sulfate	capsule	7152015
ANDA205501	TOBRAMYCIN	tobramycin	solution	7132015
ANDA205256	ESTRADIOL	estradiol	tablet	5292015
ANDA203730	DIVALPROEX SODIUM	divalproex sodium	tablet, extended release	5292015
ANDA203691	TEMOZOLOMIDE	temozolomide	capsule	5082015
ANDA090041	MEMANTINE HYDROCHLORIDE	memantine hydrochloride	tablet	4102015
ANDA201095	LEVONORGESTREL AND ETHINYL ESTRADIOL	ethinyl estradiol	tablet	12082014
ANDA201658	CALCIUM ACETATE	calcium acetate	capsule	10062014
ANDA204605	ACYCLOVIR	acyclovir	ointment	6182014
ANDA203638	OXYCODONE HYDROCHLORIDE	oxycodone hydrochloride	tablet	6032014
ANDA203751	CLOPIDOGREL BISULFATE	clopidogrel bisulfate	tablet	4112014
ANDA202960	ATOVAQUONE	atovaquone	suspension	3182014
ANDA079233	IBUPROFEN	ibuprofen	tablet	3182014
ANDA203513	CLINDAMYCIN PALMITATE HYDROCHLORIDE	clindamycin palmitate hydrochloride	for solution	3132014
ANDA201108	LEVONORGESTREL AND ETHINYL ESTRADIOL	ethinyl estradiol	tablet	2052014
ANDA200936	DICLOFENAC SODIUM	diclofenac sodium	gel	10282013
ANDA202260	NORETHINDRONE	norethindrone	tablet	8012013
ANDA203399	METAXALONE	metaxalone	tablet	6212013
ANDA200894	PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE	codeine phosphate	syrup	4242013
ANDA202202	WARFARIN SODIUM	warfarin sodium	tablet	3042013
ANDA202025	SILDENAFIL CITRATE	sildenafil citrate	tablet	2282013
ANDA203136	BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE	buprenorphine hydrochloride	tablet	2222013
ANDA202128	POTASSIUM CHLORIDE	potassium chloride	capsule, extended release	2222013
ANDA202961	OXCARBAZEPINE	oxcarbazepine	suspension	9172012
ANDA200275	NORETHINDRONE ACETATE	norethindrone acetate	tablet	7302012
ANDA202024	GABAPENTIN	gabapentin	solution	3232012
ANDA202227	ESCITALOPRAM OXALATE	escitalopram oxalate	solution	3142012
ANDA202300	IBUPROFEN	ibuprofen	capsule	12232011
ANDA202385	FELBAMATE	felbamate	suspension	12162011
ANDA201764	FLUOCINOLONE ACETONIDE	fluocinolone acetonide	oil	10172011
ANDA201759	FLUOCINOLONE ACETONIDE	fluocinolone acetonide	oil	10172011
ANDA091306	FLUOCINOLONE ACETONIDE	fluocinolone acetonide	oil/drops	10172011
ANDA078892	NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE	ethinyl estradiol	tablet	9262011
ANDA201680	FELBAMATE	felbamate	tablet	9132011
ANDA091384	RISPERIDONE	risperidone	solution	5252011
ANDA201679	NITROFURANTOIN	nitrofurantoin	suspension	5112011
ANDA201451	MECLIZINE HYDROCHLORIDE	meclizine hydrochloride	tablet	2232011
ANDA090575	PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE	dextromethorphan hydrobromide	syrup	2082011
ANDA091483	ONDANSETRON HYDROCHLORIDE	ondansetron hydrochloride	solution	1312011
ANDA091179	PROMETHAZINE HYDROCHLORIDE	promethazine hydrochloride	tablet	12132010
ANDA091549	INDOMETHACIN	indomethacin	capsule, extended release	12012010
ANDA090606	MYCOPHENOLATE MOFETIL	mycophenolate mofetil	tablet	7162010
ANDA091426	SPIRONOLACTONE	spironolactone	tablet	7022010
ANDA078826	LORAZEPAM	lorazepam	tablet	6232010
ANDA079241	ALBUTEROL SULFATE	albuterol sulfate	syrup	5122010
ANDA079098	VENLAFAXINE HYDROCHLORIDE	venlafaxine hydrochloride	tablet	5112010
ANDA078780	CETIRIZINE HYDROCHLORIDE ALLERGY	cetirizine hydrochloride	tablet	1212010
ANDA040882	PROMETHAZINE HYDROCHLORIDE	promethazine hydrochloride	syrup	12302009
ANDA091383	LORAZEPAM	lorazepam	concentrate	12232009
ANDA090485	TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN	acetaminophen	tablet	12092009
ANDA090576	NIZATIDINE	nizatidine	solution	11182009
ANDA090992	LEVETIRACETAM	levetiracetam	solution	10272009
ANDA090766	CETIRIZINE HYDROCHLORIDE	cetirizine hydrochloride	solution	10072009
ANDA090765	CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY	cetirizine hydrochloride	solution	10072009
ANDA078267	NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE	ethinyl estradiol	tablet	9012009
ANDA040902	PROMETHAZINE HYDROCHLORIDE AND PHENYLEPHRINE HYDROCHLORIDE	phenylephrine hydrochloride	syrup	8252009
ANDA078071	RISPERIDONE	risperidone	tablet	6172009
ANDA078345	PREDNISOLONE SODIUM PHOSPHATE	prednisolone sodium phosphate	solution	3102009
ANDA079096	NAPROXEN SODIUM	naproxen sodium	tablet	12162008
ANDA040765	EXTENDED PHENYTOIN SODIUM	phenytoin sodium	capsule	11122008
ANDA040808	HYDROXYZINE HYDROCHLORIDE	hydroxyzine hydrochloride	tablet	9242008
ANDA078312	RANITIDINE HYDROCHLORIDE	ranitidine hydrochloride	syrup	9022008
ANDA078258	GRANISETRON HYDROCHLORIDE	granisetron hydrochloride	injectable	6302008
ANDA078387	ALPRAZOLAM	alprazolam	tablet, extended release	5302008
ANDA040779	ACETAMINOPHEN AND CODEINE PHOSPHATE	acetaminophen	tablet	5292008
ANDA040866	PRIMIDONE	primidone	tablet	4232008
ANDA078476	FOSPHENYTOIN SODIUM	fosphenytoin sodium	injectable	3182008
ANDA065425	DEMECLOCYCLINE HYDROCHLORIDE	demeclocycline hydrochloride	tablet	2272008
ANDA078477	AMLODIPINE BESYLATE	amlodipine besylate	tablet	1162008
ANDA078596	METFORMIN HYDROCHLORIDE	metformin hydrochloride	tablet, extended release	1032008
ANDA078262	GRANISETRON HYDROCHLORIDE	granisetron hydrochloride	injectable	12312007
ANDA040777	OXYCODONE AND ACETAMINOPHEN	acetaminophen	tablet	11272007
ANDA040778	OXYCODONE AND ACETAMINOPHEN	acetaminophen	tablet	11272007
ANDA040789	OXYCODONE AND ACETAMINOPHEN	acetaminophen	tablet	11272007
ANDA040855	BETHANECHOL CHLORIDE	bethanechol chloride	tablet	11212007
ANDA078428	GABAPENTIN	gabapentin	capsule	7252007
ANDA078558	IBUPROFEN	ibuprofen	tablet	6182007
ANDA078432	NAPROXEN SODIUM	naproxen sodium	tablet	4252007
ANDA040813	HYDROCODONE BITARTRATE AND ACETAMINOPHEN	acetaminophen	tablet	2232007
ANDA077289	CITALOPRAM HYDROBROMIDE	citalopram hydrobromide	tablet	11302006
ANDA077824	RANITIDINE HYDROCHLORIDE	ranitidine hydrochloride	tablet	10132006
ANDA040769	HYDROCODONE BITARTRATE AND ACETAMINOPHEN	acetaminophen	tablet	8282006
ANDA040736	HYDROCODONE BITARTRATE AND ACETAMINOPHEN	acetaminophen	tablet	8252006
ANDA040746	HYDROCODONE BITARTRATE AND ACETAMINOPHEN	acetaminophen	tablet	8252006
ANDA040748	HYDROCODONE BITARTRATE AND ACETAMINOPHEN	acetaminophen	tablet	8252006
ANDA040754	HYDROCODONE BITARTRATE AND ACETAMINOPHEN	acetaminophen	tablet	8252006
ANDA040757	HYDROCODONE BITARTRATE AND ACETAMINOPHEN	acetaminophen	tablet	8252006
ANDA040729	HYDROCODONE BITARTRATE AND ACETAMINOPHEN	acetaminophen	tablet	8252006
ANDA077880	METFORMIN HYDROCHLORIDE	metformin hydrochloride	tablet	6052006
ANDA076820	BENAZEPRIL HYDROCHLORIDE	benazepril hydrochloride	tablet	2032006

Financials

Annual
Quarterly

$ Mil \| FY: 12/31	LTM	2025	2024	2023	2022	2021	2020
Period End	3/31/2026	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020
Filing Date	5/7/2026	2/27/2026	2/28/2025	3/14/2024	3/3/2023	3/1/2022	3/1/2021
Key Financials
Total Revenue	3,046	3,019	2,794	2,394	2,212	2,094	1,993
Gross Profit	1,178	1,113	1,020	821	785	769	628
EBITDA	626	604	440	400	150	401	346
Operating Income	445	398	348	239	189	194	111
Net Income	122	72	-117	-84	-130	11	91
EPS	0.39	0.23	-0.38	-0.48	-0.86	0.07	0.62
Growth Rates
Total Revenue Growth	7.6%	8.0%	16.7%	8.2%	5.7%	5.1%	22.5%
EBITDA Growth	14.1%	37.3%	10.0%	165.8%	-62.5%	16.1%	122.7%
Operating Income Growth	22.3%	14.2%	45.9%	26.4%	-2.6%	74.6%	180.0%
Net Income Growth	1035.9%	161.6%	-39.2%	35.4%	-1323.5%	-88.3%	125.2%
Margins
Gross Margin	38.7%	36.9%	36.5%	34.3%	35.5%	36.7%	31.5%
EBITDA Margin	20.6%	20.0%	15.7%	16.7%	6.8%	19.2%	17.3%
Operating Income Margin	14.6%	13.2%	12.5%	10.0%	8.5%	9.3%	5.6%
Net Income Margin	4.0%	2.4%	-4.2%	-3.5%	-5.9%	0.5%	4.6%
Cash & Debt
Total Cash	198	282	111	92	26	248	341
Total Debt	2,696	2,689	2,593	2,751	2,845	2,876	2,945
Net Debt / (Cash)	2,499	2,407	2,483	2,659	2,819	2,628	2,604
Cash Flows & CapEx
Net Cash from Operations	306	340	295	346	65	242	379
Total CapEx	-118	-114	-75	-69	-91	-53	-66
Free Cash from Operations	188	226	220	276	-25	189	313
Returns to Shareholders
Dividends	0	-0	-0	-0	-0	-0	-0
Share Repurchases	-0	-0	-0	-0	-0	-0	-0

$ Mil \| FY: 12/31	2026Q1	2025Q4	2025Q3	2025Q2	2025Q1	2024Q4	2024Q3	2024Q2	2024Q1	2023Q4	2023Q3	2023Q2
Period End	3/31/2026	12/31/2025	9/30/2025	6/30/2025	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023
Filing Date	5/7/2026	2/27/2026	11/6/2025	8/7/2025	5/7/2025	2/28/2025	11/12/2024	8/9/2024	5/8/2024	3/14/2024	11/9/2023	8/8/2023
Key Financials Quarterly
Total Revenue	723	814	785	725	695	731	702	702	659	617	620	599
Ebitda	177	161	112	177	155	112	140	142	46	33	131	138
Operating Income	148	115	70	112	101	78	89	96	85	49	77	76
Net Income	62	35	2	22	12	-31	-0	6	-92	-99	10	12
EPS	0.20	0.11	0.01	0.07	0.04	-0.10	0.00	0.02	-0.30	-0.40	0.06	0.08
Key Financials TTM
Total Revenue TTM	3,046	3,019	2,935	2,853	2,830	2,794	2,680	2,598	2,495	2,394	2,386	2,312
Ebitda TTM	626	604	556	584	549	440	360	351	347	400	467	442
Operating Income TTM	445	398	361	380	364	348	319	307	287	239	261	228
Net Income TTM	122	72	6	3	-13	-117	-184	-175	-169	-84	10	-2
Growth Rates Quarterly
Total Revenue Growth	3.9%	11.5%	11.7%	3.2%	5.5%	18.4%	13.3%	17.1%	18.2%	1.2%	13.7%	7.1%
EBITDA Growth	14.3%	42.9%	-20.2%	24.9%	238.2%	240.6%	6.7%	3.0%	-53.4%	-67.1%	23.4%	200.2%
Operating Income Growth	46.9%	46.7%	-20.7%	16.2%	18.6%	60.1%	15.1%	27.1%	130.1%	-31.7%	76.1%	47.7%
Net Income Growth	410.5%	212.9%	1618.6%	274.0%	113.3%	68.5%	-101.6%	-49.7%	-1219.9%	-2176.7%	460.1%	109.9%
Margins Quarterly
EBITDA Margin	24.5%	19.7%	14.2%	24.4%	22.2%	15.4%	19.9%	20.2%	6.9%	5.4%	21.1%	23.0%
Operating Income Margin	20.5%	14.1%	9.0%	15.5%	14.5%	10.7%	12.6%	13.7%	12.9%	7.9%	12.4%	12.7%
Net Income Margin	8.6%	4.3%	0.3%	3.1%	1.8%	-4.3%	-0.0%	0.9%	-13.9%	-16.0%	1.6%	2.0%
Cash & Debt
Total Cash	198	282	201	72	59	111	74	44	47	92	87	109
Total Debt	2,696	2,689	2,686	2,582	2,580	2,593	2,645	2,725	2,746	2,751	2,805	2,859
Net Debt / (Cash)	2,499	2,407	2,484	2,510	2,520	2,483	2,571	2,681	2,699	2,659	2,718	2,749
Cash Flows Quarterly
FCF from Operations	-27	130	118	84	7	118	142	40	-4	136	81	-11
Cash Flows TTM
FCF from Operations TTM	306	340	328	351	307	295	313	252	201	346	186	199
Returns to Shareholders Quarterly
Dividends	0	0	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0
Return on Invested Capital (ROIC) Quarterly
ROIC	19.7%	14.3%	9.6%	10.4%	8.9%	10.5%	8.9%	9.9%	10.6%	6.2%	9.0%	8.7%
Return on Invested Capital (ROIC) TTM
ROIC TTM	15.2%	12.7%	10.3%	7.3%	6.8%	11.7%	10.5%	9.6%	8.9%	7.5%	7.6%	5.1%

Segment Financials

Revenue by Segment

$ Mil	2025	2024	2023	2022	2021
Affordable Medicines	1,746	1,685	1,471	1,432	1,366
AvKARE	745	663	532	406	349
Specialty	529	446	390	374	378
Corporate and Other	0	0	0	0
Total	3,019	2,794	2,394	2,212	2,094

Operating Income by Segment

$ Mil	2025	2024	2023	2022	2021
Affordable Medicines	381	270	276	224	281
Specialty	116	114	65	73	56
AvKARE	84	43	32	3	7
Corporate and Other	-186	-177	-169	-395	-192
Total	394	249	204	-95	153

Price Behavior

Price Behavior

Market Price	$16.21
Market Cap ($ Bil)	5.1
First Trading Date	03/27/2018
Distance from 52W High	-0.8%
	50 Days	200 Days
DMA Price	$13.36	$12.39
DMA Trend	up	up
Distance from DMA	21.4%	30.9%
	3M	1YR
Volatility	38.0%	32.3%
Downside Capture	-20.28	68.38
Upside Capture	94.46	133.29
Correlation (SPY)	32.3%	32.9%

AMRX Betas & Captures as of 5/31/2026

	1M	2M	3M	6M	1Y	3Y
Beta	1.01	1.49	1.38	1.00	1.09	1.04
Up Beta	1.53	1.86	1.52	1.14	0.85	1.00
Down Beta	1.88	0.96	1.13	0.75	0.75	0.76
Up Capture	55%	80%	100%	95%	186%	334%
Bmk +ve Days	13	28	36	67	141	432
Stock +ve Days	9	20	29	61	132	374
Down Capture	76%	217%	174%	110%	109%	100%
Bmk -ve Days	7	13	27	57	109	318
Stock -ve Days	10	20	33	61	112	360

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively

Based On 1-Year Data

	Annualized Return	Annualized Volatility	Sharpe Ratio	Correlation with AMRX
AMRX	104.8%	32.3%	2.26	-
Sector ETF (XLV)	14.0%	15.0%	0.66	43.3%
Equity (SPY)	26.5%	12.4%	1.61	32.5%
Gold (GLD)	24.2%	27.5%	0.77	12.9%
Commodities (DBC)	19.8%	18.8%	0.83	-23.6%
Real Estate (VNQ)	11.0%	13.7%	0.52	35.2%
Bitcoin (BTCUSD)	-40.0%	42.5%	-1.08	6.6%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Based On 5-Year Data

	Annualized Return	Annualized Volatility	Sharpe Ratio	Correlation with AMRX
AMRX	22.1%	51.1%	0.57	-
Sector ETF (XLV)	5.4%	14.7%	0.19	31.6%
Equity (SPY)	13.5%	17.1%	0.62	35.5%
Gold (GLD)	17.1%	18.3%	0.76	5.3%
Commodities (DBC)	7.5%	19.4%	0.29	4.7%
Real Estate (VNQ)	1.9%	18.9%	0.00	32.0%
Bitcoin (BTCUSD)	11.0%	54.2%	0.40	15.4%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Based On 10-Year Data

	Annualized Return	Annualized Volatility	Sharpe Ratio	Correlation with AMRX
AMRX	-1.8%	64.2%	0.24	-
Sector ETF (XLV)	9.4%	16.6%	0.46	32.5%
Equity (SPY)	15.3%	18.0%	0.73	34.6%
Gold (GLD)	12.3%	16.1%	0.63	1.8%
Commodities (DBC)	5.9%	18.0%	0.26	10.7%
Real Estate (VNQ)	5.3%	20.7%	0.22	26.9%
Bitcoin (BTCUSD)	60.0%	66.8%	1.00	11.9%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Short Interest

Short Interest: As Of Date	5292026
Short Interest: Shares Quantity	7.5 Mil
Short Interest: % Change Since 5152026	-5.4%
Average Daily Volume	1.6 Mil
Days-to-Cover Short Interest	4.6 days
Basic Shares Quantity	316.0 Mil
Short % of Basic Shares	2.4%

Returns Analyses

	Title
0	Amneal Pharmaceuticals Stock Jump Looks Great, But How Secure Is That Gain?

Earnings Returns History

Updated 6/10/2026

Expand for More

	Forward Returns
Earnings Date	1D Returns	5D Returns	21D Returns
5/7/2026	-3.8%	-10.9%	-0.1%
2/27/2026	-4.7%	-8.5%	-18.2%
10/30/2025	-4.1%	12.1%	18.0%
8/5/2025	2.1%	11.1%	19.8%
5/2/2025	3.0%	-3.6%	-4.1%
2/28/2025	3.5%	4.5%	-1.2%
11/8/2024	1.4%	4.5%	-6.0%
8/9/2024	-1.5%	1.8%	8.9%
...
SUMMARY STATS
# Positive	11	11	11
# Negative	13	13	13
Median Positive	3.5%	4.5%	13.9%
Median Negative	-7.0%	-10.3%	-10.2%
Max Positive	22.3%	25.9%	40.1%
Max Negative	-16.2%	-20.3%	-36.4%

Collapse to Preview

	Forward Returns
Earnings Date	1D Returns	5D Returns	21D Returns
5/7/2026	-3.8%	-10.9%	-0.1%
2/27/2026	-4.7%	-8.5%	-18.2%
10/30/2025	-4.1%	12.1%	18.0%
8/5/2025	2.1%	11.1%	19.8%
5/2/2025	3.0%	-3.6%	-4.1%
2/28/2025	3.5%	4.5%	-1.2%
11/8/2024	1.4%	4.5%	-6.0%
8/9/2024	-1.5%	1.8%	8.9%
5/3/2024	8.9%	4.2%	6.4%
3/1/2024	-0.9%	-3.8%	9.6%
11/7/2023	2.4%	1.7%	8.1%
8/4/2023	22.3%	25.9%	25.6%
5/5/2023	4.3%	2.2%	39.1%
3/2/2023	-4.8%	-19.6%	-34.9%
11/4/2022	1.9%	14.4%	13.9%
8/5/2022	-8.1%	-15.6%	-36.4%
5/4/2022	-7.0%	-17.0%	-10.2%
3/2/2022	-9.7%	-10.3%	-5.2%
11/3/2021	-8.6%	-8.2%	-28.4%
8/9/2021	5.5%	4.9%	8.2%
5/7/2021	-10.0%	-5.2%	-1.6%
2/26/2021	10.2%	-1.2%	40.1%
11/6/2020	-16.2%	-16.2%	-14.4%
8/6/2020	-11.4%	-20.3%	-29.2%
SUMMARY STATS
# Positive	11	11	11
# Negative	13	13	13
Median Positive	3.5%	4.5%	13.9%
Median Negative	-7.0%	-10.3%	-10.2%
Max Positive	22.3%	25.9%	40.1%
Max Negative	-16.2%	-20.3%	-36.4%

SEC Filings

Expand for More

Report Date	Filing Date	Filing
03/31/2026	05/07/2026	10-Q
12/31/2025	02/27/2026	10-K
09/30/2025	11/06/2025	10-Q
06/30/2025	08/07/2025	10-Q
03/31/2025	05/07/2025	10-Q
12/31/2024	02/28/2025	10-K
09/30/2024	11/12/2024	10-Q
06/30/2024	08/09/2024	10-Q
03/31/2024	05/08/2024	10-Q
12/31/2023	03/14/2024	10-K
09/30/2023	11/09/2023	10-Q
06/30/2023	08/08/2023	10-Q
03/31/2023	05/09/2023	10-Q
12/31/2022	03/03/2023	10-K
09/30/2022	11/07/2022	10-Q
06/30/2022	08/08/2022	10-Q

Collapse to Preview

Report Date	Filing Date	Filing
03/31/2026	05/07/2026	10-Q
12/31/2025	02/27/2026	10-K
09/30/2025	11/06/2025	10-Q
06/30/2025	08/07/2025	10-Q
03/31/2025	05/07/2025	10-Q
12/31/2024	02/28/2025	10-K
09/30/2024	11/12/2024	10-Q
06/30/2024	08/09/2024	10-Q
03/31/2024	05/08/2024	10-Q
12/31/2023	03/14/2024	10-K
09/30/2023	11/09/2023	10-Q
06/30/2023	08/08/2023	10-Q
03/31/2023	05/09/2023	10-Q
12/31/2022	03/03/2023	10-K
09/30/2022	11/07/2022	10-Q
06/30/2022	08/08/2022	10-Q
03/31/2022	05/06/2022	10-Q
12/31/2021	03/01/2022	10-K
09/30/2021	11/08/2021	10-Q
06/30/2021	08/09/2021	10-Q
03/31/2021	05/07/2021	10-Q
12/31/2020	03/01/2021	10-K
09/30/2020	11/06/2020	10-Q
06/30/2020	08/06/2020	10-Q
03/31/2020	05/11/2020	10-Q
12/31/2019	03/02/2020	10-K
09/30/2019	11/07/2019	10-Q
06/30/2019	08/05/2019	10-Q

Recent Forward Guidance

Updated 5/31/2026

Latest: Q1 2026 Earnings Reported 5/7/2026

Forward Guidance				Guidance Change
Metric	Low	Mid	High	% Chg	% Delta	Change	Prior
2026 Net revenue	3.05 Bil	3.10 Bil	3.15 Bil	0		Affirmed	Guidance: 3.10 Bil for 2026
2026 Adjusted EBITDA	740.00 Mil	755.00 Mil	770.00 Mil	2.0%		Raised	Guidance: 740.00 Mil for 2026
2026 Adjusted diluted EPS	0.95	1	1.05	2.0%		Raised	Guidance: 0.98 for 2026
2026 Operating cash flow	350.00 Mil	375.00 Mil	400.00 Mil	7.1%		Raised	Guidance: 350.00 Mil for 2026
2026 Operating cash flow, excluding discrete items	375.00 Mil	400.00 Mil	425.00 Mil	6.7%		Raised	Guidance: 375.00 Mil for 2026
2026 Capital expenditures		110.00 Mil		0		Affirmed	Guidance: 110.00 Mil for 2026

Prior: Q4 2025 Earnings Reported 2/27/2026

Forward Guidance				Guidance Change
Metric	Low	Mid	High	% Chg	% Delta	Change	Prior
2026 Net revenue	3.05 Bil	3.10 Bil	3.15 Bil	1.6%		Raised	Guidance: 3.05 Bil for 2025
2026 Adjusted EBITDA	720.00 Mil	740.00 Mil	760.00 Mil	8.8%		Raised	Guidance: 680.00 Mil for 2025
2026 Adjusted diluted EPS	0.93	0.98	1.03	26.5%		Raised	Guidance: 0.78 for 2025
2026 Operating cash flow	325.00 Mil	350.00 Mil	375.00 Mil	11.1%		Raised	Guidance: 315.00 Mil for 2025
2026 Capital expenditures		110.00 Mil		10.0%		Raised	Guidance: 100.00 Mil for 2025
2026 Operating cash flow, excluding discrete items	350.00 Mil	375.00 Mil	400.00 Mil
2026 Affordable Medicines net revenue growth	7.0%	7.5%	8.0%
2026 AvKARE net revenue	625.00 Mil	662.50 Mil	700.00 Mil

Insider Activity

Updated 5/12/2026

Expand for More

#	Owner	Title	Holding	Action	Filing Date	Price	Shares	Transacted Value	Value of Held Shares	Form
1	Autor, Deborah M		Direct	Sell	5122026	12.94	34,819	450,558	1,211,960	Form
2	Nark, Ted C		Direct	Sell	11192025	11.72	50,000	586,000	3,410,860	Form
3	Shah, Nikita	Executive Vice President	Direct	Sell	11142025	11.92	131,856	1,571,724	1,745,124	Form
4	Kiely, John		Direct	Sell	8282025	9.23	32,000	295,360	2,080,747	Form
5	Shah, Nikita	Executive Vice President	Direct	Sell	8252025	9.50	6,340	60,230	1,390,828	Form

Collapse to Preview

#	Owner	Title	Holding	Action	Filing Date	Price	Shares	Transacted Value	Value of Held Shares	Form
1	Autor, Deborah M		Direct	Sell	5122026	12.94	34,819	450,558	1,211,960	Form
2	Nark, Ted C		Direct	Sell	11192025	11.72	50,000	586,000	3,410,860	Form
3	Shah, Nikita	Executive Vice President	Direct	Sell	11142025	11.92	131,856	1,571,724	1,745,124	Form
4	Kiely, John		Direct	Sell	8282025	9.23	32,000	295,360	2,080,747	Form
5	Shah, Nikita	Executive Vice President	Direct	Sell	8252025	9.50	6,340	60,230	1,390,828	Form
6	Shah, Nikita	Executive Vice President	Direct	Sell	8252025	9.66	114,492	1,105,993	1,475,497	Form
7	Boyer, Andrew S	Executive Vice President	Direct	Sell	8222025	9.38	279,244	2,619,309	1,429,756	Form
8	Konidaris, Tasos	Executive Vice President & CFO	Direct	Sell	8152025	9.43	219,159	2,066,669	1,151,893	Form
9	Shah, Nikita	Executive Vice President	Direct	Sell	8152025	9.29	71,694	666,037	2,482,613	Form
10	Konidaris, Tasos	Executive Vice President & CFO	Direct	Sell	8152025	9.30	119,206	1,108,616	3,174,192	Form
11	Konidaris, Tasos	Executive Vice President & CFO	Direct	Sell	8152025	9.22	161,365	1,487,785	4,245,967	Form
12	Shah, Nikita	Executive Vice President	Direct	Sell	8132025	9.04	50,000	452,000	3,063,918	Form
13	Daly, Jason B	EVP, Chief Legal Officer	Direct	Sell	8132025	9.05	22,000	199,100	95,984	Form
14	Boyer, Andrew S	Executive Vice President	Direct	Sell	8132025	9.05	33,436	302,596	2,322,864	Form
15	Patel, Gautam		Direct	Sell	6182025	8.02	94,906	761,146	12,905,335	Form
16	Patel, Gautam		Direct	Sell	6122025	8.02	56,426	452,537	13,666,481	Form
17	Shah, Nikita	Executive Vice President	Direct	Sell	5192025	7.58	49,140	372,481	2,948,082	Form
18	Kiely, John		Direct	Sell	5132025	7.59	50,000	379,500	1,953,916	Form
19	Patel, Gautam		Direct	Sell	5052025	8.00	4,900	39,200	13,761,744	Form
20	Patel, Gautam		Direct	Sell	5052025	8.00	3,768	30,144	13,800,944	Form

AMRX Trade Sentinel

Stock Conviction

null

CONVICTION RATIONALE

null

STOCK ARCHETYPE

null

Looking for high-conviction positions with a better risk/reward profile? See what's currently in the Trefis High Quality Portfolio.

INVESTMENT THESIS

null

Mechanism: null

Supporting Evidence:

PRIMARY RISK

null

Mechanism: null

Supporting Evidence:

Key KPI Watchlist

KPI	Threshold	Rationale

Core Investment Debate

BULL VIEW

CORE TENSION

PREVAILING SENTIMENT

BEAR VIEW

Next 6 months: Risks and Catalysts

Timeline	Event & Metric To Watch

Key Events in Last 6 Months

Date	Event	Stock Impact

Risk Management

Position Sizing

Diversification Alternatives

How Is The Market Pricing AMRX?

What will confirm the thesis

What will damage the thesis

Noise: Real but irrelevant to thesis

Repricing Catalyst

What AMRX Makes & Who Pays

TTM figures based on

AMRX Evolution: Price Return by Era

① Structure

② Volume / Momentum

③ Catalyst

Combined Score

0 / 12

1 Price Structure & Trend · ▾

2 Momentum ▾

3 Relative Strength vs. SPY ▾

4 Institutional Footprint & Volume ▾

5 Volatility ▾

6 Key Price Levels Range · Vol ▾

7 Earnings Reaction History ▾

8 How the Verdict Is Derived Three Pillars ▾

Pillar	Score
① Structure	0
② Vol / Mom	0
③ Catalyst	0

ℹ Bull Pillars: 0 · Bear Pillars: 0 · Combined Score: 0 →

Industry Resources

Health Care Resources

U.S. National Library of Medicine

Health Data Management

FDA Tracker

Pharmaceuticals Resources

Fierce Pharma

Pharm Exec

Endpoints News

External Quote Links

0	Y Finance	Barrons
1	TradingView	Morningstar
2	SeekingAlpha	ValueLine
3	Motley Fool	Robinhood
4	CNBC	Etrade
5	MarketWatch	Unusual Whales
6	YCharts	Perplexity Finance
7	FinViz

Prefer one of these to Trefis? Tell us why.

Core Cache Last Updated: 6/19/2026

Amneal Pharmaceuticals (AMRX)

Market Price (6/20/2026): $16.21 | Market Cap: $5.1 BilSector: Health Care | Industry: Pharmaceuticals

Amneal Pharmaceuticals (AMRX)

Market Price (6/20/2026): $16.21Market Cap: $5.1 BilSector: Health CareIndustry: Pharmaceuticals

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

AMRX in ETFs

Valuation & Metrics

Price Chart

Why The Stock Moved

Qualitative Assessment

Stock Movement Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Return vs. Risk

Price Returns Compared

How Low Can It Go

In The Past

Preserve Wealth

Asset Allocation

In The Past

Preserve Wealth

Asset Allocation

About Amneal Pharmaceuticals (AMRX)

Major Products and Services of Amneal Pharmaceuticals (AMRX)

Generics Segment

Specialty Segment

Central Nervous System (CNS) Disorders

Endocrinology

Parasitic Infections (Emverm)

Parkinson's Disease (Rytary)

Hypothyroidism (Unithroid)

Share Issuance

Capital Expenditures

Interactive Breakdown

Better Bets vs. Amneal Pharmaceuticals (AMRX)

INDUSTRY: Pharmaceuticals

Higher Rev Chg 3Y Avg | Lower P/S (Values for AMRX: 10.3% | 1.7x)

Higher Rev Chg 3Y Avg | Lower P/Op Inc (Values for AMRX: 10.3% | 11.5x)

Higher Rev Chg LTM (Value for AMRX: 7.6%)

Higher Rev Chg 3Y Avg (Value for AMRX: 10.3%)

Higher Op Mgn LTM (Value for AMRX: 14.6%)

Higher CFO/Rev LTM (Value for AMRX: 10.0%)

Higher FCF/Rev LTM (Value for AMRX: 6.2%)

Higher Total Yield (Value for AMRX: 2.4%)

SECTOR: Health Care

Higher Rev Chg 3Y Avg | Lower P/S (Values for AMRX: 10.3% | 1.7x)

Higher Rev Chg 3Y Avg | Lower P/Op Inc (Values for AMRX: 10.3% | 11.5x)

Higher Rev Chg LTM (Value for AMRX: 7.6%)

Higher Rev Chg 3Y Avg (Value for AMRX: 10.3%)

Higher Op Mgn LTM (Value for AMRX: 14.6%)

Higher CFO/Rev LTM (Value for AMRX: 10.0%)

Higher FCF/Rev LTM (Value for AMRX: 6.2%)

Higher Total Yield (Value for AMRX: 2.4%)

All Other Sectors

Higher Rev Chg 3Y Avg | Lower P/S (Values for AMRX: 10.3% | 1.7x)

Higher Rev Chg 3Y Avg | Lower P/Op Inc (Values for AMRX: 10.3% | 11.5x)

Higher Rev Chg LTM (Value for AMRX: 7.6%)

Higher Rev Chg 3Y Avg (Value for AMRX: 10.3%)

Higher Op Mgn LTM (Value for AMRX: 14.6%)

Higher CFO/Rev LTM (Value for AMRX: 10.0%)

Higher FCF/Rev LTM (Value for AMRX: 6.2%)

Higher Total Yield (Value for AMRX: 2.4%)

Best Bets in Health Care

P/EBIT (Value for AMRX: 12.2x)

P/E (Value for AMRX: 41.9x)

Rev Chg 3Y Avg (Value for AMRX: 10.3%)

Rev Chg LTM (Value for AMRX: 7.6%)

Rev Chg Q (Value for AMRX: 3.9%)

FCF/Rev 3Y Avg (Value for AMRX: 6.5%)

Latest Trefis Analyses

Trade Ideas

Recent Active Movers

Top Gainers

Top Losers

Market Price (6/20/2026): $16.21
Market Cap: $5.1 Bil
Sector: Health Care
Industry: Pharmaceuticals